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SUMMARY 
Metastasis is a multistep process depending on complex interactions between tumor cells 
and the stromal compartment which also contains immune cells and soluble factors such as 
chemokines. The presence of certain classes of monocytes in malignant tumors is frequently 
a result of chemoattractants such as CCL2 and correlates with enhanced tumor cell 
extravasation and metastasis. Selectins are vascular adhesion receptors, well-known to 
facilitate metastasis by mediating the contact between tumor cells and cells in the metastatic 
environment. Particularly E-selectin is thought to mediate the arrest of tumor cells in the 
vasculature by binding to E-selectin ligands on tumor cells and thereby promoting 
metastasis. This study aimed to elucidate whether E-selectin facilitates metastasis by 
interacting with other constituents of the metastatic microenvironment.  
Experimental metastasis of tumor cells without E-selectin ligands to the lungs was attenuated 
in E-selectin deficient mice. This phenotype can already be determined during early 
metastatic phases. Lung analysis within the first hours after tumor cell injection revealed 
reduced expression of endothelial activation markers and the chemokine CCL2 in E-selectin 
deficient mice. Endothelial activation includes E-selectin up-regulation in C57BL/6 mouse 
lungs and was shown to be partially dependent on tumor cell-derived CCL2. However, 
endothelial cells and recruited monocytes were identified as the main sources of CCL2 in the 
metastatic lungs. The total pool of CCL2 in metastatic lungs was decreased in the absence 
of E-selectin. This is linked to the reduced leukocyte infiltration observed in E-selectin 
deficient lungs upon tumor cell injection. Association of infiltrated leukocytes with tumor cells 
was E-selectin dependent. Moreover, monocyte-supported tumor cell transmigration required 
binding of E-selectin to monocyte ligands. In the presence of E-selectin, tumor cells together 
with monocytes induced endothelial cell retraction. Accordingly, the lung vasculature was 
less permeable in E-selectin deficient or monocyte-depleted mice after tumor cell injection. 
E-selectin deficient mice also showed decreased spontaneous lung metastasis. Our study 
identifies a novel mechanism how E-selectin-leukocyte interactions supported by CCL2 
induce vascular permeability, which promotes tumor cell extravasation and metastasis.   
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ZUSAMMENFASSUNG 
Die Metastasierung von Tumoren ist ein mehrstufiger Prozess, welcher von komplexen 
Interaktionen zwischen Tumorzellen und dem Stroma, wie zum Beispiel Immunzellen und 
Chemokinen abhängt. Das Chemokin CCL2 ist in Primärtumoren präsent und zieht 
Monozyten an, deren Anzahl in malignen Tumoren häufig mit erhöhter Extravasation von 
Tumorzellen und dem Auftreten von Metastasen korreliert. Selectine sind vaskuläre 
Adhäsionsmoleküle und bekannt dafür die Metastasierung zu fördern, indem sie den Kontakt 
zwischen Tumorzellen und endogenen Bestandteilen ihrer Umgebung ermöglichen. Es wird 
vermutet, dass besonders E-selectin die Metastasierung begünstigt durch die Vermittlung 
der Anhaftung von Tumorzellen an die Vaskulatur. Diese Studie hatte das Ziel 
herauszufinden ob E-selectin die Metastasierung unterstützt, indem es auch mit anderen 
Komponenten des metastatischen Umfeldes interagiert. 
Die Metastasierung von Tumorzellen ohne E-selectin Liganden zur Lunge war verringert in 
E-selectin-defizienten Mäusen in experimentellen Metastasenmodellen. Dieser Phänotyp war 
schon während frühen metastatischen Phasen erkennbar. Die Analyse von Lungengewebe 
während der ersten Stunden nach Tumorzellinjektion zeigte reduzierte Expression von 
endothelialen Markeren und dem Chemokin CCL2 in E-selectin-defizienten Mäusen. 
Endotheliale Aktivierung beinhaltet die Hochregulierung von E-selectin in Lungen von 
C57BL/6 Mäusen was teilweise vom Tumorzell-stammenden CCL2 abhängig war. 
Endothelzellen und inflammatorische Monozyten wurden jedoch als die wichtigere Quelle 
von CCL2 in der metastatischen Lunge identifiziert. Der Gesamtpool von CCL2 in der 
metastatischen Lunge war reduziert in Abwesenheit von E-selectin. Dies stand im 
Zusammenhang mit der reduzierten Infiltration von Leukozyten in die Lungen von Mäusen 
ohne E-selectin nach Tumorzellinjektion. Die Assoziation von infiltrierten Leukozyten mit 
Tumorzellen war E-selectin abhängig und die Monozyten-unterstützte Tumorzell-
Transmigration benötigte das Binden von E-selectin an Liganden von Monozyten. 
Tumorzellen und Monozyten zusammen lösten die Retraktion von E-selectin exprimierenden 
Endothelzellen aus. Demzufolge war die Lungenvaskulatur weniger durchlässig in Mäusen 
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ohne E-selectin oder nach Depletion von Monozyten vor der Tumorzellinjektion. E-selectin-
defiziente Mäuse wiesen auch weniger spontane Metastasierung in der Lunge auf. Unsere 
Studie identifizierte einen neuen Mechanismus der beschreibt wie die Interaktion zwischen 
E-selectin und Leukozyten, unterstützt durch CCL2, vaskuläre Permeabilität erzeugt und 
dadurch die Extravasation von Tumorzellen und Metastasierung begünstigt.   
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LIST OF ABBREVIATIONS 
CAFs:    cancer associated fibroblasts 
CCL2 (MCP-1):  CC chemokine 2 (monocyte chemoattractant protein-1) 
CCR2:    CC chemokine receptor 2 
CD:    cluster of differentiation 
DCs:    dendritic cells 
DR3:    death receptor 3 
ECM:    extracellular matrix 
EGF:    epidermal growth factor 
EMT:    epithelial-to-mesenchymal transition 
ERK:     extracellular-signal regulated kinase 
ESL-1:    E-selectin ligand-1 
FGF:    fibroblast growth factor 
G-CSF:   granulocyte-colony stimulating factor 
GlyCAM-1:   glycosylation-dependent cell adhesion molecule-1 
HUVECs:   human umbilical vein endothelial cells 
ICAM-1:   intracellular adhesion molecule-1 
IFN-γ:    interferon-γ 
IL:    interleukin 
iNOS:    inducible nitric oxide synthase 
JNK:    c-Jun-N-terminal kinase 
LOX:    lysyl oxidase 
M1/N1:   pro-inflammatory macrophages/neutrophils, M1/N1 phenotype 
M2/N2:   pro-tumor macrophages/neutrophils, M2/N2 phenotype 
MAdCAM-1:   mucosal addressin cell adhesion molecule-1 
MAPK:    mitogen-activated protein kinase 
M-CSF/CSF-1:  (macrophage-) colony stimulating factor(-1)  
MDSCs:   myeloid-derived suppressor cells 
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MMP:    matrix metalloproteinase 
NF-κB:    nuclear factor kappa B    
NK cell :   natural killer cell 
PDGF:    platelet-derived growth factor 
PI3K:    phosphatidylinositol 3 kinase 
PLC:    phospholipase C 
PNAd:    peripheral lymph node addressin 
PSGL-1:   P-selectin glycoprotein ligand-1 
ROS:    reactive oxygen species 
SCID:    severe combined immunodeficiency  
SDF-1:    stromal derived factor-1 
sLex/a:    sialyl-Lewisx/a 
STAT3:   signal transducer and activator of transcription 3 
TAMs:    tumor associated macrophages 
TANs:    tumor associated neutrophils 
TF:    tissue factor 
TGF-β:   transforming growth factor-β   
TME:    tumor microenvironment 
TNF-α:    tumor necrosis factor-α 
Tregs:    regulatory T-cells 
uPA:    urokinase plasminogen activator 
VAP-1:    vascular adhesion protein-1 
VCAM-1:   vascular adhesion molecule-1 
VEGF:    vascular endothelial growth factor 
VEGFR:   vascular endothelial growth factor receptor 
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INTRODUCTION 
1. Metastasis 
Metastasis is the process of cancer spreading to organs distant from the original tumor and 
constitutes a serious clinical problem. At the time of primary tumor diagnosis, metastasis has 
often already occurred and accounts for the death of the majority of cancer patients. Current 
therapeutic approaches directly target primary tumor progression whereas the prevention of 
metastasis provides a major challenge since our understanding of this complex process is 
still incomplete. Unravelling the intricate series of events during the metastatic cascade will 
therefore lead to new possibilities for therapeutic intervention.  
 
1.1 The metastatic cascade: concepts and mechanisms 
To successfully metastasize, tumor cells need to detach from the primary tumor mass and 
cross the endothelial lining to enter the blood stream. Tumor cells encounter many 
environmental challenges but can also cooperatively interact with host cells during 
intravascular transition. These interactions influence the metastatic potential of tumor cells 
and allow them to actively shape their environment, enabling them to exit the vascular 
system at secondary sites (Figure 1). 
 
 
Figure 1. Metastatic cascade.  
Hematogenous metastatic dissemination 
involves the following steps: ① Tumor cell 
detachment from the primary tumor site; ② 
Migration of tumor cells through the extracellular 
matrix; ③ Intravasation into blood vessels; ④ 
Tumor cell association with platelets and 
leukocytes; ⑤ Extravasation of tumor cell 
emboli and establishment of new metastatic 
lesions. 
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1.1.1 Concepts of metastasis 
As discussed above, tumors can spread via the bloodstream which is known as 
hematogenous metastasis or via the lymphatic system to neighboring lymph nodes 
(lymphogenic metastasis). Since distant metastasis predominantly relies on hematogenous 
dissemination (1) this thesis focusses on metastasis via the blood stream.  
Primary tumors constantly release millions of tumor cells into the circulation but nevertheless 
only very few metastases are established (2,3). In experimental animal models less than 
0.01% of intravenously injected B16F1 melanoma cells were finally able to establish lung 
metastatic tumors (2,4). Later it was shown that most melanoma cells arrest in the 
microvasculature and extravasate into the liver parenchyma but fail to from persistent 
micrometastases in an experimental liver metastasis assay (5). Thus, metastasis is an 
inefficient process due to the fact that most tumor cells fail to execute successfully all steps 
of the metastatic cascade.  
It has long been recognized that certain types of cancers specifically metastasize to distinct 
organs. For instance, breast cancer frequently spreads to bone, liver, brain and lungs 
whereas prostate cancers prefer to metastasize to bone. In turn, patients with colorectal 
cancer often show development of metastasis in the liver (3). This observation led to the 
formulation of the “seed and soil hypothesis” which explains that organ-specific 
dissemination patterns are a result of cancer cells (“the seed”) that are dependent on the 
environment (“the soil”) at the secondary organ (6). This view on metastasis was challenged 
by another hypothesis, which suggested that circulation pattern between a primary tumor and 
a secondary organ determine the organ specificity of metastasis (J. Ewing, Neoplastic 
Diseases, vol. 16, 6th edition, 1928). Both hypotheses are not mutually exclusive and current 
research supports a role for both concepts. Overall, circulating tumor cells will be 
preferentially taken to specific secondary sites depending on blood flow patterns but once 
tumor cells encounter a secondary organ, successful establishment of metastasis will 
depend on their compatibility with the organ’s environment (3,7).  
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An important parameter to predict the course of disease and therapeutically intervene with 
metastasis is the time point of cancer cell dissemination. Originally, metastasis was 
considered the final step in cancer progression. Current evidence from disease courses of 
different cancer types and genetics of disseminated tumor cells favors the parallel 
progression model (8) which proposes metastasis as an early event taking place before 
acquisition of fully malignant phenotypes (9-12).  
 
1.1.2 Tumor cells in circulation 
Cancer patients with solid tumors frequently have circulating tumor cells in their blood and a 
subset of these cells will eventually be able to establish metastatic tumors in distant organs 
(13,14). Most tumor cells get physically trapped in the microvasculature due to size 
restrictions within minutes after entering the circulation. However tumor cells in circulation 
and during initial arrest are also exposed to shear stress and to immune cells, especially 
natural killer (NK) cells so that not all arrested cells will form metastatic foci (3). During their 
short passage through the blood stream tumor cell properties enable them to escape the 
hostile environment in the blood vasculature. Tumor cell expressed tissue factor (TF) has 
been shown to trigger the formation of thrombin leading to coagulation as well as platelet 
activation, which has been associated with enhanced metastasis (15-19). The resulting fibrin 
binds to tumor cells as well as to activated platelets via integrins and thereby generates 
tumor cell-fibrin-platelet aggregates. Thus, activation of the coagulation cascade leads to 
platelet accumulation around tumor cells forming a protective barrier against shear stress 
and lysis by NK cells (15,20-23). Tumor cell interactions with platelets via P-selectin also 
significantly contribute to the formation of platelet-tumor cell thrombi (24,25) and will be 
discussed later. Many experimental models have identified platelets as crucial promoters of 
metastasis (26-30). Both platelet-derived TGF-β and platelet-derived growth factor (PDGF) 
have been shown to impair and suppress NK cell function (31,32). High platelet counts and 
coagulation are associated with poor clinical outcome (23,33,34).  
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Permanent adhesion to the endothelium is most probably mediated by specific interactions 
between tumor cells, immune cells and the vasculature. It is generally accepted that primary 
tumors are able to form so-called pre-metastatic niches which provide a supportive 
environment for incoming cancer cells (35-38). The primary tumor as well as tumor cell 
emboli themselves can activate the endothelium and platelets thereby mobilizing and 
recruiting different types of bone marrow derived cells (e.g. immature myeloid cells, 
neutrophils and monocytes) (38-43). The activated state of the endothelium may favor 
adhesion of tumor cells partially mediated by adhesion molecules such as selectins and 
other vascular adhesion molecules (25,44,45). Myeloid-derived cells in the metastatic 
microenvironment support tumor cells during the early stages of metastasis by promoting 
survival and facilitating extravasation of metastasizing cells (46).  
 
1.1.3 Tumor cell extravasation 
After intravascular arrest, tumor cells need to traverse the endothelium to successfully invade 
the parenchyma of a secondary organ. The observation that different tumor cells 
preferentially seed to different organs can be partially explained by the type of vasculature in 
the secondary organ. Bone marrow sinusoid capillaries for instance consist of fenestrated 
endothelia, normally facilitating leukocyte trafficking and are therefore permissive to 
circulating tumor cells (47). The fenestrated liver capillaries are also more likely to be 
crossed by tumor cells compared to other organs (48-50). On the contrary, pulmonary 
endothelial cells are surrounded by a basement membrane which impedes simple 
endothelial transmigration by tumor cells (51-54). Tumor cells produce specific mediators 
that enable them to bypass the capillary walls (55). For instance breast cancer cells have 
been shown to overexpress the adhesion molecule metadherin, which specifically binds to 
the vasculature in the lung and enhances metastasis (56). The concerted actions of 
chemokines and chemokine receptors expressed by tumor cells and the local environment 
contribute to tumor cell extravasation (57,58). Remarkably, all the initial interactions between 
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tumor cells and leukocytes, platelets or endothelial cells are primarily mediated by selectins 
which are considered to be major drivers of the metastatic process (25,59). 
 
2. Selectins 
Selectins are cell surface adhesion molecules that mediate the initial attachment of 
leukocytes to the endothelium during leukocyte extravasation at sites of inflammation and 
lymphocyte patrolling (60,61). Selectins are type-I transmembrane proteins consisting of an 
N-terminal calcium-dependent lectin domain, an epidermal growth factor-like (EGF) domain, 
two to nine consensus repeats, a single-pass transmembrane domain and a short cytosolic 
domain (62) (Figure 2).  
 
Figure 2. Structure of selectins.  
L-, P-, and E-selectin share a similar 
structure composed of a N-terminal 
calcium-dependent lectin domain, an 
epidermal growth factor-like (EGF) 
domain, 2, 9 or 6  consensus repeat 
units (L-, P- and E-selectin, 
respectively), and a single-pass 
transmembrane domain followed by 
a short cytosolic domain (62). 
 
The selectin family contains three members that are L-, P-, and E-selectin which share 
around 50% sequence homology in their C-type lectin domain (60). Although the three 
selectins share many common elements they differ in the regulation of their expression, cell 
type specificity and binding specificities. L-selectin (LECAM-1, CD62L) is constitutively 
expressed by most hematopoietic cell types such as myeloid cells, lymphocytes, naïve T-
cells or NK cells (60,63). L-selectin is best known as a mediator of leukocyte adhesion to the 
endothelium and to ligands expressed on high endothelial venules of the peripheral lymph 
nodes (64,65). P-selectin (PADGEM, CD62P) is stored in alpha-granules of unstimulated 
platelets as well as in Weibel-Pallade bodies of resting endothelial cells. Upon activation of 
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platelets or the endothelium P-selectin can be rapidly recruited to the cell surface. P-selectin 
plays an important role during platelet aggregation at sites of vascular injury while endothelial 
P-selectin contributes to leukocyte recruitment. E-selectin (ELAM-1, CD62E) is exclusively 
displayed by endothelial cells and expressed de novo in response to inflammatory stimuli 
such as TNF-α and IL-1β and mediates leukocyte rolling at sites of inflammation or injury. 
There is certain evidence for constitutive E-selectin expression in the skin and parts of the 
bone marrow (66). 
 
2.1 Factors that regulate E-selectin expression 
The expression of E-selectin is regulated by cytokines such as TNF-α and IL-1β which 
activate signaling pathways including JNK/p38 mitogen-activated protein kinase (p38 MAPK) 
and transcription factors like NF-κB and activator protein-1 (67-69). The amount of E-selectin 
on the cell surface peaks around 2 to 6 hours after stimulation and returns to its basal levels 
within 24 hours (70,71). In addition, other factors like shear stress (72), vascular endothelial 
growth factor (VEGF) (73), monocytes (74) and the activation of Rho family GTPases (75) 
trigger or prolong E-selectin expression. Cytokines such as TGF-β (76), glucocoriticoids (77) 
and the histamine H2-receptor antagonist cimetidine (78) suppress E-selectin expression.  
 
2.2 Selectin ligands  
The minimal carbohydrate motifs that are recognized by the lectin domain of all three 
selectins are the tetrasaccharide sialyl-Lewisx and sialyl-Lewisa (79) (Figure 3). Sialyl-Lewisx 
(sLex; Neu5Ac α2,3 Galβ1,4 [Fuc α1,3] GlcNAc-R) is a terminal structure on N- or O-linked 
glycans attached to glycoproteins and glycolipids displayed by most circulating leukocytes 
and endothelial cells. Sialyl-Lewisa however (sLea; Neu5Ac α2,3 Galβ1,3 [Fuc α1,4] GlcNAc-
R) is found on limited types of epithelial cells but mostly on tumor cells (59,80). The four 
glycosyltransferases N-acetylglucosaminyltransferase, β1,4-galactosyltransferase, α2,3-
sialyltransferase and α1,3-fucosyltransferase-4 or -7 sequentially synthesize sialyl-Lewisa/x 
carbohydrates in cells of the hematopoietic system (60) (59,61,81). Selectin ligands are often 
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located in clusters on glycoprotein scaffolds of the cell membrane which enables efficient 
binding of respective ligands (60). Modifications such as sulfation of the protein backbone or 
the carbohydrate recognition structure itself increase binding efficiency (82). Both P- and L-
selectin can bind to sulfated glycans such as heparin, heparin sulfate, fucoidan and sulfated 
glycolipids (83,84). 
 
Figure 3. Structure of sialyl-Lewis
a
 and sialyl-Lewis
x
 (adapted from Juge et al., 2012, Trends in 
Microbiology). 
Neu5Ac α2,3 Galβ1,3 [Fuc α1,4] GlcNAc-R represents the structure of sialyl-Lewis
a
 whereas Neu5Ac 
α2,3 Galβ1,4 [Fuc α1,3] GlcNAc-R describes the structure of sialyl-Lewis
x
. 
 
To date P-selectin glycoprotein ligand-1 (PSGL-1) is one of the most thoroughly 
characterized ligands for all three selectins (65,85). PSGL-1 is concentrated on the tips of 
microvilli on the surface of leukocytes (86). Additional modifications of PSGL-1 core 
structures including sulfation of tyrosines Tyr48 and Tyr51 near the N-terminus of the protein 
potentiates binding of PSGL-1 to P- and L-selectin but not to E-selectin (87). PSGL-1 knock 
out mice have delayed neutrophil recruitment and moderate neutrophilia, similarly to P-
selectin knock out mice (85,88). While P-selectin is the main receptor for PSGL-1, E-selectin 
also interacts with PSGL-1 besides other ligands such as E-selectin ligand-1 (ESL-1) and 
CD44. The interaction between E-selectin and PSGL-1 enables leukocyte capturing by the 
endothelium whereas the interactions of ESL-1 and CD44 with E-selectin mediate rolling of 
leukocytes (89). L-selectin binding to PSGL-1 expressed on leukocytes is thought to mediate 
collisional cell-cell interactions which initiate leukocyte aggregation thereby further recruiting 
inflammatory cells during pathological conditions (64). Other L-selectin ligands are primarily 
expressed on the luminal surface of high endothelial venules and play an important role for 
lymphocyte homing to secondary lymphatic tissues. These ligands comprise a 
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heterogeneous group of molecules called the peripheral lymph node addressin (PNAd) group 
which includes the glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1), CD34, 
podocalyxin and endomucin. The mucosal addressin cell adhesion molecule-1 (MAdCAM-1) 
that is expressed in the gut on endothelial lymphatic tissue is also recognized by L-selectin 
(61).   
 
2.3 Physiological roles of selectins 
Selectins are critical regulators of leukocyte trafficking, like lymphocyte homing to secondary 
lymphoid tissues through high endothelial venules (90) or recruitment and extravasation of 
innate immune cells during pathophysiological conditions (91) (Figure 4). 
During leukocyte recruitment and extravasation innate immune cells leave the intravascular 
compartment to enter sites of inflammation, infection or injury. This process involves several 
 
Figure 4. Leukocyte extravasation cascade.  
Leukocyte extravasation is initiated by tethering ① of circulating leukocytes followed by rolling ② on 
the endothelium which is generally mediated by transient selectin–glycan ligand interactions and/or 
integrin interactions with vascular adhesion molecule-1 (VCAM-1) or intracellular adhesion molecule-1 
(ICAM-1). During rolling, leukocytes are exposed to endothelial signals (such as chemokines) that 
trigger firm adhesion ③ to the endothelium by activating integrins on the leukocyte surface. 
Subsequently, leukocytes crawl along the vessel wall and ultimately migrate across the endothelium 
into the extravascular space ④ (adapted from Kunkel et al., 2003, Nature Reviews Immunology). 
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tightly regulated steps such as selectin-mediated rolling on the endothelial cell layer, firm 
adhesion to the endothelia via integrins followed by leukocyte crawling and finally 
transmigration into the associated tissue (91-94) (Figure 4). During inflammation leukocyte 
recruitment mostly takes place in post capillary venules where hemodynamic shear forces 
are low.  
 
2.3.1 The role of selectins during leukocyte rolling  
The leukocyte adhesion cascade starts with freely circulating immune cells binding to the 
vessel wall which initiates their rolling along the endothelial lining. Rolling allows capturing of 
immune cells by the endothelium and is enabled by endothelial selectin binding to selectin 
ligands on leukocytes. During leukocyte rolling there is constant binding and release between 
selectins and their ligands due to their low affinity towards each other (95). Stagnating blood 
flow leads to the detachment of cells (95) while increased shear stress further strengthens 
binding (96). Studies with P-selectin deficient mice revealed a severe impairment of 
leukocyte rolling under inflammatory conditions (97). Although the speed of granulocyte 
rolling is increased in inflamed venules of E-selectin deficient mice, (98) the lack of E-selectin 
reveals no significant impairment of leukocyte recruitment in several models of inflammation 
(99). L-selectin is responsible for lymphocyte homing to peripheral lymph nodes (90) and 
upon binding to ligands extracellular domains of L-selectin can be rapidly shed from the 
leukocyte surface by proteolytic cleavage (100,101). L-selectin shedding possibly modulates 
the velocity of leukocyte rolling and regulates the degree of inflammation (102). The Inhibition 
of L-selectin shedding results in increased adhesion and transmigration of leukocytes due to 
prolonged leukocyte activation (103). Conversely, lymphocyte homing and leukocyte 
recruitment is affected in L-selectin deficient mice (104).  
 
2.3.2 The role of integrins during leukocyte rolling  
Next to selectins, integrins are another class of surface proteins expressed by leukocytes 
that can influence their rolling properties. Integrins are transmembrane receptors consisting 
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of α and β subunits and mediate cell-cell and cell-extracellular matrix (ECM) interactions. 
Integrins shift between different conformational states which determine their affinity towards 
the respective ligand. Furthermore, integrins are also capable of transducing signals across 
the cell membrane in both directions (105). α4β1 (VLA-4), α4β7 (LPAM), αLβ2 (LFA-1) and 
αMβ2 (Mac1, CD11b) are integrins which are expressed by leukocytes. α4β1 (VLA-4) binds 
to VCAM-1 and α4β7 interacts with VCAM-1 as well as with MAdCAM-1 and mediate 
leukocyte rolling independently of selectins (106-108).  
 
2.3.3 Rolling-induced activation and signaling in leukocytes 
The binding of selectins to their ligands induces intracellular signaling in the selectin- as well 
as selectin ligand-expressing cell (109-111). The signaling cascade which is induced in 
leukocytes by engaging with PSGL-1 is well studied and starts with signal transduction via 
immunoreceptor tyrosine-based activation motif- (ITAM-) containing adaptor molecules ezrin 
and moesin  (110-112). These proteins link plasma membranes to actin cytoskeleton and are 
important for signaling during cell movement (113). Subsequently several non-receptor 
tyrosine kinases (e.g. Syk, Hek, Lyn, Btk) get activated and transmit signals to phospholipase 
C (PLC) and phosphatidylinositol 3 kinases (PI3K). This induces Calcium and DAG regulated 
guanine nucleotide exchange factor I (CalDAG-GEF-I) and MAP kinase p38 signaling 
pathways which activate Ras-related protein 1 (RAP 1). This leads to the recruitment of the 
FERM-containing protein talin to the cytoplasmic tail of integrins which mediates the 
changing of integrin conformation to an intermediate affinity state. As a consequence 
neutrophil rolling is slowed down (91,109,114-117).  
 
2.3.4 Firm leukocyte arrest  
In general selectin- or integrin-mediated rolling slows down leukocytes (95) and allows them 
to sense signals in the inflammatory environment. This enables chemokines, either bound to 
glycosaminoglycans such as heparan sulfate (118) on the endothelium or secreted by local 
macrophages, to activate G-protein coupled chemokine receptors (GPCR) on the leukocyte 
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cell surface (119). Actually, both selectin- and chemokine signaling pathways are required 
during leukocyte recruitment to fully activate integrins. These signaling events shift integrin 
conformation to an intermediate affinity state resulting in slower rolling of leukocytes (117). 
Consequently, chemokine signals accumulate thereby eliciting further conformational 
changes which finally leads to fully activated high affinity integrin conformations. This 
enables firm adhesion of leukocytes to their counter receptors presented on endothelial cells 
(119). Integrin and chemokine signaling during activation and firm adhesion of leukocytes 
also includes a distinct change in morphology of leukocytes. Thereby the round shape of 
rolling cells is transformed into a polarized morphology characterized by an F-actin rich front 
(lamellipodium) and a trailing edge (uropod) in which the cytoskeleton is contracted during 
migration. These changes allow the cells to coordinate intracellular forces required during 
crawling and subsequent transmigration (120-125). 
 
2.3.5 Trans-endothelial migration  
After selectin- and chemokine-induced, integrin-dependent leukocyte arrest, adhesion to 
endothelial cells is strengthened and lekocytes undergo cytoskeletal reorganization to spread 
and crawl along the vessel wall where they find a suited location for transmigration (also 
called diapedesis) through the endothelial lining (91). Diapedesis of leukocytes is either 
paracellular (through endothelial junctions) or transcellular (through the endothelial cell itself) 
(126,127). A recent study showed that approximately 90% of neutrophils exit the blood 
vessels via the paracellular pathway (128). The conditions which favor or determine the 
transmigration route of different leukocytes are currently not fully elucidated (129). 
Transmigrating cells interact with endothelial junctional molecules such as ICAM-1 which 
activates signaling pathways that elevate intracellular Ca2+ levels in endothelial cells (128-
130). This is followed by the activation of myosin-light chain kinase causing cell contractions 
that open up adherens junctions between endothelial cells (130,131). Finally, VE-cadherin-β-
catenin complexes that are indispensable for stabilization of endothelial junctions (129), 
dissociate what enables the opening of endothelial contacts. As a consequence, permeability 
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of endothelial cells is locally increased which enables leukocyte transmigration. Before 
reaching the interstitium, leukocytes need to pass the basement membrane that underlies 
the endothelial cell layer and the pericytes. Among others, integrin α6β1, PECAM-1 as well 
as basement membrane degrading proteases like the matrix metalloproteinases secreted by 
leukocytes help them to overcome the basement membrane (91,132-134).  
 
2.3.6 Activation and signaling in endothelial cells upon E-selectin-ligand interaction 
It has become apparent that engagement of E-selectin by its ligands on leukocytes also 
induces “outside-in” signaling in endothelial cells (135). After leukocyte binding to E-selectin 
or other events that mimic this process (e.g. antibody-mediated cross-linking or ligand-coated 
beads), a physical interaction of E-selectin with the actin cytoskeleton via its cytoplasmic 
domain is initiated and E-selectin clustering at the endothelial surface in the vicinity of 
adhering leukocytes is observed (136). E-selectin/ligand-interactions trigger the 
dephosphorylation of a usually phosphorylated serine residue in the cytoplasmatic domain of 
E-selectin (137). This signal seems to extend the half-life of E-selectin at the cell surface 
(138). At the same time a tyrosine residue (Tyr603) is phosphorylated, activating MAP kinase 
signaling pathways and consequently inducing transcriptional activation of the immediate 
early response gene c-fos (139,140). E-selectin has been demonstrated to localize into 
cholesterol-rich lipid rafts at the cell surface and upon ligation E-selectin is clustered and 
redistributed with a fraction of plasma membrane associated caveolin-1 containing rafts. 
After binding to a respective ligand, E-selectin that is localized in these lipid rafts associates 
with PLC-γ and drives its activation during leukocyte-endothelial interactions (135). There is 
also evidence indicating that the activation of E-selectin triggers cytoskeletal remodeling 
leading to the disruption of the VE-cadherin-β-catenin complex via the p38 MAP kinase 
signaling pathway and thereby regulating trans-endothelial permeability (51,141-143). 
Altogether, numerous in vitro studies show that E-selectin functions as an “outside-in” 
signaling receptor and highlight the importance of E-selectin as a regulator of endothelial 
barrier integrity. 
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2.4 Selectins in inflammatory diseases  
Selectins are crucial for resolving infections and healing wounds however aberrant homing of 
leukocytes mediated by selectins has been associated with chronic or acute inflammatory 
pathologies, such as asthma (144-146), psoriasis (147-149), arthritis (150), acute ischemic 
stroke injuries (151) or with progression of cancer. E-selectin may also be involved in 
cardiovascular diseases since elevated levels have been found in hypertension, diabetes 
and hyperlipidemia (152).  
 
2.5 Role of selectin-selectin ligand axis in tumor dissemination 
All three selectins have been demonstrated to contribute towards tumor dissemination and is 
attributed to their ability to promote cell-cell interactions with tumor cells in their environment. 
Selectins specifically regulate adhesive interactions between circulating tumor cells and 
blood constituents such as platelets, leukocytes, and endothelial cells, thereby modulating 
the metastatic cascade at different steps (25,153-156).  
During malignant transformation, physiological selectin ligands including PSGL-1, ESL-1, 
CD24, sLex, sLea, CD34, MAdCAM-1, lysosomal membrane glycoproteins LAMP-1 and 
LAMP-2, sulfatides, CD44 and death receptor 3 (DR3) that are normally presented by 
leukocytes can be up-regulated on the surface of tumor cells (157). Evidence obtained from 
clinical studies and in vitro data using human carcinoma cells as well as animal models with 
selectin deficiencies imply an important link between selectins and altered glycosylation on 
tumor cell ligands. It has been demonstrated that tumor cells which express sialylated or 
fucosylated molecules can be recognized by selectins (25,153,158-160) and that enhanced 
sLex and sLea expression correlates with poor prognosis due to enhanced tumor progression 
and metastatic spreading (161-163).  
 
2.5.1 Carcinoma mucins 
One example of an aberrantly expressed and glycosylated selectin ligand on carcinoma cells 
are mucin-type glycoproteins which bind to all three types of selectins. Mucins are high 
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molecular weight glycoproteins exhibiting a rod like conformation due to glycosylation with 
complex oligosaccharides, mainly constituting O-linked glycans (164,165). Mucin 1 (MUC1), 
MUC2, MUC4 and MUC16 are the most common mucins associated with cancer progression 
(165-168). Mucins exhibit glycan structures such as sLex, sLea, sialyted T and Tn antigens 
(169) which have long been associated with the progression of epithelial cancer and poor 
clinical prognosis of many human carcinomas such as colon cancer (170). By mediating 
adhesion to carcinoma mucins, platelet expressed P-selectin in combination with L-selectin is 
probably involved in triggering thromboembolic events in cancer patients described as 
Trousseau syndrome. This hypothesis is based on the observation that the injection of 
carcinoma cells into mice rapidly induced formation of platelet-rich microthrombi. Mice 
deficient in P- and L-selectin showed reduced microthrombi formation (171). Moreover, 
platelet-tumor aggregation and metastasis was attenuated by the enzymatic removal of 
selectin ligand carrying mucins from tumor cells before injecting them into the tail vein (172).  
 
2.5.2 Sialyl-Lewisx/a during tumor progression and metastasis 
Compelling clinical and experimental data demonstrates that overrepresentation of the 
tetrasaccharides sLex and sLea on tumor cell surfaces correlates with poor prognosis by 
potentiating metastatic behavior of various cancer types such as colon, gastric, prostate, 
renal, pancreatic and lung cancer (161,173-178). Human colon carcinoma cells with high 
sLex surface presentation showed more efficient colonization into the liver than cells 
expressing low levels of sLex in experimental metastasis models (179). sLea presence on the 
surface of colon cancer cells improved the growth of subcutaneous xenografts which was 
associated with enhanced angiogenesis (180).  
Increased levels of sLex/a on tumor cells have been attributed to the elevated expression of 
fucosyltransferase-7 which has also been shown to correspond with increased malignancy in 
lung cancer patients (174) and was further shown to be highly expressed in many colon 
cancer cell lines (181). The fucosyltransferases-3 and -6 have also been shown to be 
involved during sLex synthesis in multiple cancer cell lines and in colorectal cancer biopsies 
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(182-184). Studies investigating prostate and pancreatic cancer cell homing into bones 
revealed that E-selectin-mediated adhesion is dependent on elevated activity of the α1,3-
fucosyltransferases-3, -6 or -7 (185,186). The genes encoding the sLex synthesizing 
fucosyltransferases-3 and -4 as well as ST3 β-galactoside α-2,3-sialyltransferase 6 
(ST3GAL6), were found to be significantly overexpressed in breast cancers which correlated 
with metastasis to the bone where the sLex receptor E-selectin is constitutively expressed 
(187). Inflammatory cytokines such as TNF-α might also influence the production of sLex and 
contribute to metastasis by stimulating the expression of genes involved during the synthesis 
of selectin ligands (188).   
 
2.5.3 P-selectin during the metastatic process 
The association between circulating tumor cells and platelets, and the formation of tumor 
microemboli has been well established (30,189,190,191). Multiple studies have 
demonstrated that hematogenous dissemination, intravascular tumor cell survival and 
metastasis are enhanced by platelets (20,21,192,193). The adhesive interactions between 
platelets and tumor cells have been found to be primarily mediated by P-selectin. In P-
selectin deficient mice, platelet-tumor cell interactions were significantly reduced and as a 
result these mice displayed attenuated metastasis (24). It was shown that platelet-
association with tumor cells also prevented NK-mediated lysis of tumor cells (20). P-selectin 
accumulation around tumor cells is supposed to primarily occur during the initial phase of 
tissue colonization (194). In the last few years specific selectin ligands have been identified 
on tumor cells which interact with P-selectin. One example is the sLex motif carrying CD24, a 
mucin-type glycosylphosphatidylinositol (GPI)-linked cell surface glycoprotein that has been 
characterized as a P-selectin ligand (45,195,196) expressed by breast carcinoma cells. 
Chondroitin sulfate glycosaminoglycans on breast cancer cells function as P-selectin ligands 
and play an important role during breast cancer metastasis (197). Interestingly, it has been 
recently shown that pro-metastatic effects of platelets occurred earlier than the anti-
metastatic effects of NK cells in murine lung metastasis models (193). This indicates other 
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mechanisms for the platelet-mediated facilitation of metastasis besides the concept of 
platelets shielding tumor cells form NK cell destruction. Next to platelet expressed P-selectin, 
endothelial P-selectin-mediated interactions were also shown to contribute to metastasis 
(193).  
 
2.5.4 L-selectin during the metastatic process  
L-selectin binds to a variety of tumor cells and participates during metastasis (153,198). In 
experimental metastasis assays, the injection of human and murine tumor cells into L-
selectin deficient mice decreased the L-selectin mediated recruitment of leukocytes to tumor 
cell emboli and consequently attenuated metastasis. Synthesis of L-selectin ligands by 
fucosyltransferase-7 occurred around cancer cell emboli and correlated with the recruitment 
of leukocytes to intravascular tumor cell emboli (194,199). There is evidence that P- and L-
selectin synergistically contribute to metastasis since metastasis has been attenuated in P- 
and L-selectin double deficient mice (194). These findings corroborate an active and dual 
role of L-selectin during metastasis which either facilitates leukocyte recruitment or 
interactions within the metastatic microenvironment. The enhanced infiltration of 
inflammatory cells, especially myeloid-derived cells is a hallmark of the tumor 
microenvironment and a well-characterized promoter of tumor growth and metastatic 
dissemination (39,41). L-selectin mediated recruitment of myeloid cells to metastatic sites 
may contribute towards the formation of the metastatic niche and promote early steps during 
metastasis, like tumor cell extravasation (43,199). Leukocyte interaction with the endothelium 
is known to induce vascular permeability during inflammatory processes. L-selectin 
presumably exerts is pro-metastatic effects by promoting an inflammatory microenvironment 
as well by directly interacting with tumor cells.  
 
2.5.5 E-selectin during the metastatic process 
The role of E-selectin during the metastatic process has been extensively studied during the 
past 30 years (156,157). Numerous clinical trials and plentiful experimental data led to the 
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hypothesis that E-selectin facilitates metastatic dissemination to distant organs by binding to 
ligands expressed on tumor cells comparable to leukocyte adhesion during inflammation 
(164).  
In patients with metastasis high serum levels of E-selectin have been observed (200,201). 
This indicates that vascular E-selectin expression is increased in these patients as E-selectin 
is known to shed from the cell surface after expression and ligation (202). Increased E-
selectin serum levels are associated with poor prognosis in patients with cancer cells 
expressing sLex (200,203,204). Numerous experiments in vitro applying physiological flow 
conditions provide evidence that tumor cells adhere to activated endothelium via their E-
selectin ligands (155,205,206). As an example LS174T colon adenocarcinoma cells that 
possess sLex on glycoproteins and glycolipids were shown to adhere to HUVECS under 
physiological flow conditions in vitro (155). Human colon and hepatic carcinoma cells display 
sLex decorated core 2 branched O-linked carbohydrates which strongly bind to E-selectin 
and regulate invasiveness (184,205).  
In vitro assays also revealed that cancer cell binding to endothelial E-selectin activates 
signaling pathways in endothelial cells which favor metastatic dissemination. E-selectin 
activation by colon cancer cells triggered the activation of both p38 and MAP kinases thereby 
inducing cytoskeletal remodeling (143,207). This generated breaches in the endothelial layer 
consequently facilitating extravasation of adhering cancer cells. The activation of E-selectin 
by binding its ligand disrupted the VE-cadherin-β-catenin complex in endothelial cells, which 
stabilizes cell-cell contacts, thereby contributing to E-selectin induced trans-endothelial 
permeability (143). These findings provide insights into mechanisms by which the adhesion 
of cancer cells to endothelial E-selectin may regulate the metastatic process.  
 
2.5.5.1 E-selectin ligands involved in the metastatic process  
Multiple E-selectin ligands that are expressed by cancer cells have been identified and linked 
to enhanced metastasis whereas most of them are mucin type molecules. Beside mucins, 
other E-selectin ligands presented on colon cancer cells have been characterized including 
INTRODUCTION  
30 
CD44, DR3, LAMP-1 and LAMP-2 (153,208-210). The CD44 transmembrane glycoprotein is 
involved during cell survival, cell adhesion, invasiveness, migration and angiogenesis (211) 
and is expressed by epithelial and endothelial cells as well as by multiple cancer cell types 
such as gastric, colorectal, pancreatic and lung cancer cells (212-214). Colorectal carcinoma 
cells that aberrantly express CD44 have an enhanced metastatic potential in vivo (215,216). 
Another E-selectin ligand is DR-3 which belongs to the TNF receptor family and was recently 
identified as a sialylated signaling ligand for E-selectin (208). Normally DR-3 is expressed by 
peripheral blood leukocytes and lymphocyte-rich tissue (217). DR-3 was also found to be 
expressed by metastatic colon cancer cells. Binding of DR-3 to endothelial E-selectin 
induced signaling via the MAP kinase p38 and thereby increased endothelial permeability 
and subsequently trans-endothelial migration of tumor cells (143,208).  
The amount of E-selectin ligands is thought to determine the adhesive phenotype of cancer 
cells. Knocking down the often up-regulated fucosyltransferase-3 on circulating pancreatic 
cancer cells disrupted their adhesion to E-selectin in vitro (182). High mRNA levels of the 
enzyme core 2 β1,6-N-acetylglucosaminyltransferase (C2GnT1) which synthesizes the E-
selectin ligand C2-O-sLex, have been found in colorectal adenocarcinomas (218). Such 
tumors were associated with vessel invasion, increased depth of tumor invasion and 
metastasis (219-221).  
 
2.5.5.2 Experimental evidence in vivo for E-selectin as facilitator of metastasis  
There is profound evidence that E-selectin promotes cancer metastasis in animal models. E-
selectin expression was increased during metastatic liver colonization and down-regulation of 
E-selectin attenuated liver metastasis (143,222). In mice that overexpressed E-selectin in the 
liver, metastasis was redirected to the liver from the lungs in an experimental lung metastasis 
assay (223). This result provided direct evidence that E-selectin promotes tumor cell 
seeding. In line with this data, experimental liver metastasis of human colon carcinoma cells 
was also E-selectin-dependent (154). In contrast, metastasis of human colon 
adenocarcinoma was unchanged in an experimental lung metastasis model using 
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immunodeficient E-selectin knockout mice (224). Evidence from spontaneous metastasis 
models showed that primary tumors secrete factors which activate endothelial focal adhesion 
kinase and E-selectin in the lung vasculature and thereby induce the formation of 
hyperpermeable foci in lungs (225). This ultimately led to enhanced homing of cancer cells to 
these sites which correlated with metastasis. These findings imply that primary tumors are 
capable of actively priming and forming a distant metastatic niche by upregulating molecules 
involved in tumor cell-endothelial cell adhesion. Both E- and P-selectin have recently been 
shown to play a role during spontaneous metastasis formation into the bone marrow as well 
as into lungs in a xenograft model of human breast cancer (226).  
Compelling clinical and experimental evidence support the concept of E-selectin as a 
facilitator of metastasis by enabling tumor cell adhesion to the vasculature. Nevertheless, 
many studies in vivo with E-selectin deficient mice do not provide exact mechanisms on how 
tumor cells interact with endothelial E-selectin and there is also controversial data about the 
organ and cancer cell type specific role of E-selectin during metastasis. Thus, details of the 
contribution of endothelial E-selectin to metastasis remain to be defined.  
 
3. Primary tumor microenvironment 
Cancer was previously considered a disease involving cells that had obtained oncogenic 
mutations which drive hyperproliferation and therefore tumor development and progression. 
During the past decades it has become evident that tumor cells do not cause cancer on their 
own. Bidirectional communication between tumor cells, normal tissue and bone marrow 
derived cells is essential to sustain tumor growth and progression. Tumor cells and stromal 
cells shape a tumor microenvironment (TME), which consists of resident structures such as 
endothelial cells and fibroblasts. These cell types provide a source of chemokines, cytokines 
and growth factors that mediate the recruitment of non-residential, infiltrating immune cells 
(227-229) (Figure 5). 
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Figure 5. Components of a primary tumor. 
A primary tumor mass consists of a complex microenvironment comprising various cell types which 
can be classified into resident and non-residential cells. Endothelial cells from the blood and lymphatic 
circulation, pericytes, stromal fibroblasts and mesenchymal stem cells are residential cells while bone-
marrow derived cells such as macrophages, neutrophils, myeloid-derived suppressor cells, mast cells 
and lymphocytes are non-residential cells that infiltrate the primary tumor (adapted from Joyce et al., 
2009, Nature Reviews Cancer). 
  
3.1 Cancer-associated fibroblasts 
Fibroblasts are part of the connective tissue, where they deposit ECM and basement 
membrane components. They can also modulate the differentiation of cells, immune 
responses and homeostasis (230,231). The tumor milieu contains high numbers of 
fibroblasts, so called cancer-associated fibroblasts (CAFs), which differ from normal 
fibroblasts. In breast cancer for example, CAFs can promote motile mesenchymal-like tumor 
cell morphology and thereby enhance the ability of malignant mammary epithelial cells to 
metastasize (232). In contrast normal fibroblasts favor an epithelial-like phenotype and 
suppress metastasis (232). The origin of CAFs during cancer development has not been 
completely elucidated (233). One hypothesis is that they arise from tumor-associated 
endothelial cells which detach from blood vessels to generate multipotent mesenchymal cells 
during epithelial-to-mesenchymal transition (EMT) (234). Several factors such as TGF-β, 
monocyte chemoattractant protein-1 (MCP-1/CCL2), platelet-derived growth factor (PDGF), 
fibroblast-growth factor (FGF) and secreted proteases can activate CAFs in the tumor 
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microenvironment (231,233). In turn, activation enables CAFs to supply the tumor milieu with 
secreted factors such as VEGF, which is known to induce vascular permeability and 
angiogenesis thereby supporting tumor progression (235).  
 
3.2 Tumor vasculature  
During angiogenesis neovascularization from pre-existing endothelial cells takes place, 
increasing the supply of the growing tumor with oxygen and nutrients. Angiogenesis has 
therefore been recognized as a key hallmark of cancer (236). Concerted interactions 
between cells from the TME, including vascular endothelial cells, pericytes and bone-marrow 
derived precursor cells enable tumor vascularization (237). Mesenchymal stem cells as well 
as CAFs are key players during tumor vascularization by secreting a variety of pro-
angiogenic signals (238). Also cancer cells often express pro-angiogenic factors like VEGF 
that favor activation of angiogenic vessles (239). Endothelial cell-expressed factors including 
adhesion molecules (e.g. ICAM-1, VCAM-1, E- and P-selectin, hyaluronan) and chemokines 
such as IL-8, CCL2 and stromal-derived factor-1 (SDF-1) support the establishment  of a 
vascular niche within the tumor milieu which promotes tumor progression and invasion 
(240,241). Endothelial cells have ECM remodeling capacities by secreting various proteases 
such as disintegrin, metalloproteinase domain containing protein 17 (ADAM17), matrix 
metalloproteinase (MMP) 2 or MMP10 and hence promote tumor growth (240). Tumor-
associated blood vessels are not only involved during the promotion of tumor growth but also 
enable malignant cells to intravasate and disseminate (242). Activated endothelial cells also 
play an important role during the recruitment of immune cells to the neoplastic 
microenvironment where they regulate tumor angiogenesis (243).  
 
3.3 Tumor-infiltrating immune cells 
Inflammation and impaired immune responses have long been associated with 
tumorigenesis. Both are based on complex interactions between tumor and immune cells 
within the TME (244). Leukocyte infiltrates contribute a substantial fraction of the TME and 
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are centrally involved during neoplasm development. While some bone marrow-derived cells 
in the tumor milieu exhibit tumor-suppressive functions such as cytotoxic T-lymphocytes and 
NK cells, other types of leukocytes, especially innate immune cells including mast cells, 
immature myeloid cells, granulocytes and macrophages exert pro-tumorigenic effects. Upon 
entering the tumor mass, some leukocytes become alternatively activated and promote 
immune tolerance, tissue remodeling, cancer cell survival, angiogenesis, tumor growth and 
metastasis (245). 
 
3.3.1 Tumor-associated macrophages 
Tumor-associated macrophages (TAMs) are derived from peripheral reservoirs (e.g. bone 
marrow or spleen) or are residential in the tissue where they crucially regulate multiple 
aspects of tumor progression. Increased numbers of macrophages in a tumors stroma 
correlate with poor prognosis in many cancer diseases (246-249), has been linked to 
proliferation and survival of malignant cells, escape from immunosurveillance, angiogenesis, 
stroma remodeling, increased tumor size and metastasis formation (41,250-252).  
Circulating macrophages primarily get recruited to tumors due to high concentration of tumor-
derived chemoattractants such as the chemokines CCL2, CCL5, macrophage-colony 
stimulating factor (M-CSF/CSF-1), VEGF and PDGF (253-257). CCL2 for example is a well-
recognized driver of macrophage infiltration in experimental and human tumors (258,259). 
CSF-1-mediated macrophage recruitment into neoplastic microenvironments is involved 
during malignant progression, angiogenesis and pulmonary metastasis in mouse models of 
aggressive metastatic mammary carcinogenesis (256,260).  
Macrophages exhibit a plastic phenotype due to their capability to differentiate into various 
polarized cell stages depending on different environmental stimuli. This explains the 
disparate roles of macrophages during normal tissue homeostasis, infection and 
tumorigenesis. Classically activated M1 macrophages (i.e. by LPS/IFN-γ) are characterized 
by the production of pro-inflammatory cytokines including IL-1, IL-10, IL-23, TNF-α and 
CXCL-10 and can kill microorganisms as well as tumor cells via the Myd88/toll-like receptor 
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pathway (261,262). IL-4-, IL-10- and IL-13-exposed (263,264) monocytes on the other hand 
differentiate into M2 polarized macrophages and elicit anti-inflammatory responses which 
promote tumorigenesis (262,265). Environmental stimuli such as NF-κB-mediated 
inflammation as well as tumor hypoxia have been identified as regulators of TAM 
programming (266,267). Hypoxic regions in tumors have been shown to attract TAMs while 
also being associated with angiogenesis and an invasive phenotype (253). Upon arrival in 
the tumor microenvironment, TAMs produce factors such as EGF, members of the FGF 
family, TGF-β, VEGF, IL-6, IL-10, chemokines and proteases including urokinase-type 
plasminogen activator (uPA), MMP2 and 9 (268-271). These TAM-expressed proteins affect 
tumor proliferation and angiogenesis while driving dissolution of the connective tissues 
thereby favoring tumor cell invasion and migration (272,273).  
 
3.3.2 Myeloid-derived suppressor cells 
During pathological conditions such as sepis or cancer, myeloid cell differentiation is 
impaired, consequently giving rise to a heterogenous population of immature myeloid cells 
that exert immunosuppressive functions and are therefore termed myeloid-derived 
suppressor cells (MDSCs) (274). MDSCs are a mixture of monocyte- and granulocyte-like 
cells that are generated and released by the bone marrow after various stimuli (275). A 
common feature of this heterogeneous cell population is the repression of T-lymphocyte and 
NK cell effector functions (274,276). Therefore, tumor-infiltrating MDSCs are crucial 
regulators of cancer progression by compromising both innate and adaptive immunity by 
interfering with mechanism of immunosurveillance (277). Cancer patients have elevated 
numbers of MDSCs, which positively correlates with advanced disease and therapeutic 
inefficacy (278-280). In animal models, MDSCs have been shown to promote tumor 
progression as depletion with neutralizing antibodies significantly diminished metastasis 
(277,281,282). The janus tyrosine kinase and signal transducer and activator of transcription 
3 (STAT3) is one of the most central transcription factors responsible for MDSC expansion in 
the tumor milieu (283). STAT3 up-regulation and reactive oxygen species (ROS) production 
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by MDSCs is induced by tumor cell-expressed factors such as VEGF and the inducible nitric 
oxide synthase (iNOS) and controlled MDSC recruitment and their immunosuppressive 
actions (284). STAT3 inhibition eliminated the suppressive activity of MDSCs in mice (285).  
The immunosuppressive functions of MDSCs are attributed to T-cell suppression by cell-cell 
contact and the release of soluble mediators such as nitric oxide, ariginase-1, ROS or 
suppressive cytokines and chemokines (286,287). In B16F10 tumor bearing mice, MDSCs 
were shown to produce large amounts of the chemokine CCL5, which is required for 
melanoma cells and intratumoral regulatory T-cell (Tregs) expansion (288). Furthermore, 
MDSCs are capable of skewing the differentiation of CD4+ T-cells to Tregs (289), polarizing 
macrophages to an M2 phenotype, impairing DC function and promoting angiogenesis (290).  
 
3.3.3 Tumor-associated neutrophils 
Several solid tumor types are infiltrated with neutrophils, including promyelocytes and mature 
granulocytes (291,292). Neutrophils are attracted to tumors and activated by diverse 
chemokines in the tumor microenvironment such as CXCL8 (IL-8), macrophage inflammatory 
protein-1 (MIP-1/CCL3) and granulocyte chemotactic protein-2 (GCP-2/CXCL6) (293-297). 
Similar to macrophages, neutrophils have a dual role during tumorigenesis. Transferring 
neutrophils into tumors has been shown to slow down tumor growth (298,299). But tumor-
associated neutrophils (TANs) promoted malignancy by secreting growth stimulating signals, 
matrix-degrading proteases and angiogenic factors (300). These observations gave rise to 
the concept of anti-tumoral N1 and pro-tumoral N2 TANs which proposes neutrophil 
polarization and plasticity is regulated by the TME. TGF-β is thought to polarize TANs to a 
pro-tumoral N2 state and prevent the generation of a N1 stage. N1-like TANs express 
immunoactive cytokines and chemokines, have diminished arginase levels, exert enhanced 
abilities in killing tumors cells and activate cytotoxic T-lymphocytes (301). N2-like TANs on 
the other hand are a major source of CXCR4, VEGF and MMP-9 which support pro-tumoral 
functions and the production of SDF-1, IL-6 and CCL2 in the tumor milieu which further 
elevates neutrophil influx and survival (302). Oppositely, neutrophil-derived MMP-8 protects 
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against tumor development in animal models (303). Neutrophils also have cytotoxic and 
cytostatic functions by generating ROS upon activation which was shown to lyse various 
tumor cell types (304-308). However, extensive ROS action can be genotoxic and therefore 
result in pro-tumoral effects (309). Another way how N1-like TANs induce cell cytotoxicity is 
by influencing the activation state of CD8+ T-cells by secreting cytokines, arginase and/or by 
activating dendritic cells (DCs) (301,310,311). 
 
3.3.4 Lymphocytes in the tumor microenvironment 
Tumor-infiltrating lymphocytes can favor the prognosis of tumors but some types of 
lymphocytes are also associated with pro-tumoral activities (312-315). One of the key players 
in cytotoxic anti-tumoral actions is the NK cell. In mouse models, NK cells promoted rejection 
of transplanted tumors, which was dependent on the presence or absence of NK cell 
receptor ligands on tumor cells. In contrast to other cytotoxic lymphocytes, NK cells are 
capable of killing cells by releasing perforin in the absence of tumoral MHC class I 
expression (316-320). NK cells play a fundamental role during tumor surveillance and further 
exhibit regulatory functions by interacting with DCs, macrophages, T-cells and endothelial 
cells (321-324). The role of NK cells in killing cancer cells was demonstrated in several 
melanoma mouse models, colon cancer, lung cancer and breast cancer (315,325-331). 
Another class of lymphocytes recruited to the TME are cytotoxic CD8+ T-cells which identify 
and kill cancer cells through tumor antigen recognition on MHC molecules (313). Similar to 
NK cells, CD8+ T-cells produce perforin, granzyme B and high amounts of IFN-γ and have 
been shown to participate in tumor immunosurveillance in several animal cancer models 
(332-334). In melanoma patients, CD8+ T-cells are present in high amounts in the circulation 
and found in metastatic lesions (335,336). Adoptively transferring cytotoxic T-lymphocytes 
into tumors is therapeutically effective in murine tumor models and is therefore emerging as 
a promising anti-cancer treatment (337).  
A further substantial fraction of tumor-infiltrating lymphocytes are Tregs which can be 
observed in melanoma, lung and ovarian carcinomas, breast and colon cancers (338-342). 
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Due to their ability to inhibit effector functions of many immune cells such as T- and B-cells, 
DCs, macrophages and NK cells, Tregs are associated with suppressing anti-tumor activities 
and therefore favor the escape from immunosurveillance (343,344). However, Treg 
infiltration has also been associated with good prognosis in some types of cancers such as 
ovarian, bladder, head/neck and colorectal tumors (313,345). The mechanisms behind anti-
tumoral actions of Tregs are still under investigation and are probably a consequence of the 
specific tumor milieu, which attracts different subtypes of Tregs (228,313).  
CD4+ TH1- and TH2-cells were also shown to play a role in the tumor microenvironment (346). 
While TH1-cells can suppress tumor related inflammation, TH2-cells exert tumor protective 
actions (347,348). 
Although DCs do not belong to the lymphocytic lineage it’s worth noting their important 
function as a link between the innate and adaptive immune system within the TME. Tumor-
associated DCs possess the unique ability to present tumor-specific peptides to T-
lymphocytes and thereby most probably elicit tumor-specific immune responses leading to 
rejection of tumors (336,349). On the contrary, the immunosuppressive tumor milieu can 
impair DC functions and consequently lead to failed T-cell activation (350,351). 
 
3.3.5 E-selectin in primary tumors 
The role of E-selectin in the primary tumor microenvironment is controversial and not 
completely understood. Reports claim that E-selectin is specifically up-regulated in 
melanoma by SDF-1α, which is thought to be critically involved in melanoma invasiveness 
(352). By down-regulating E-selectin, the homing of endothelial progenitor cells to the tumor 
and thus angiogenesis was markedly reduced, resulting in inhibited tumor growth of human 
melanoma xenografts in a SCID mouse model. Eliminating the E-selectin ligand-synthesizing 
α1,3-fucosyltransferases in a murine transgenic prostate adenoma model dramatically 
reduced cancer incidences (353). These findings suggest that E-selectin is engaged in pro-
tumoral activities. However, selectins were also shown to contribute to tumor suppression by 
enabling the infiltration of anti-tumorigenic bone marrow-derived cells including macrophages 
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(354). The loss of E-selectin increased the growth of primary subcutaneous B16 melanoma 
cells, which was associated with reduced infiltration of NK cells, CD4+ T-cells and CD8+ T-
cells (355). Clinical data demonstrate that high E-selectin expression correlates with 
improved survival in patients with Merkel cell carcinomas. In many Merkel cell carcinomas E-
selectin expression is lost which is associated with poor intratumoral CD8+ T-cell infiltration 
(356). This implies that E-selectin is the primary adhesion molecule for many types of tumor-
suppressive immune cells. Vascular E-selectin expression in the tumor microenvironment 
may play a dual role and its effects on tumor progression might depend on different tumor 
cell types as well on the characteristics of the tumor milieu.   
 
3.4 Metastasis initiating processes in the tumor microenvironment  
In order to colonize distant organs tumor cells undergo phenotypic switching by acquiring 
specific features that enable them to free themselves from the primary tumor mass. The 
stromal compartment of a tumor contributes to tumor cell invasion and metastasis by 
enhancing invasive traits of tumor cells, enabling tumor cell detachment and by establishing 
a permissive environment at the target organ, the so called pre-metastatic niche (Figure 6). 
Disaggregation of cancer cells from the tumor mass requires the loss of cell-cell adhesion 
within the primary tumor. Cadherin-catenin complexes maintain tight intercellular adhesive 
interactions (357). The loss of E-cadherin is a characteristic of invasive cancer cells and has 
been strongly linked with a metastatic phenotype (358-360). In numerous cancers including 
breast (361), gastrointestinal (362) and pancreatic cancers (363) a loss or down-regulation of 
E-cadherin has been observed. In a murine model of pancreatic cancer the disruption of E-
cadherin resulted in early invasiveness and metastasis (358). To enter the blood stream, 
tumor cells must become motile and gain migratory traits. To achieve this they undergo an 
“epithelial-to-mesenchymal transition” (EMT) where they transform form a sedentary 
epithelial to a motile mesenchymal phenotype. EMT is mediated by molecules such as TGF-
β, MAP kinases and the transcriptional regulators Twist, Snail, Wnt and Notch (364). Motile 
tumor cells are less sensitive to apoptosis (365) and more responsive to chemokine 
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gradients (366). Mesenchymal-type tumor cells are able to use proteases such as MMPs, 
cathepsins and uPA to degrade the ECM and the basement membrane (367-372). Once 
tumor cells have migrated though the stromal compartment and overcome the epithelial 
basement membrane and surrounding ECM, they reach tumor-associated vessels which are 
often not fully developed and therefore leaky (373) which facilitates cancer cell intravasation 
(374). Tumor vessel normalization that is characterized by increased vessel density, pericyte 
coverage and perfusion and decreased vessel size was reported to reduce metastasis (375).  
Stromal cell interactions with cancer cells play a fundamental role in supporting tumor cells to 
traverse structural boundaries of the primary tumor to reach the blood stream. TAMs produce 
factors such as FGF, EGF, PDGF, SDF-1 and proteases such as MMPs or cathepsins (376) 
which have been reported to enhance tumor cell migration and invasiveness (242,377,378). 
Mice with defective macrophages achieved by deleting the CSF-1 gene displayed impaired 
metastasis of breast cancer cells to the lungs (243,379). Other factors such as cytokines and 
growth factors that are released into the tumors stroma also provide pro-metastatic 
advantages. The cytokine TGF-β produced by stromal cells induces the expression of 
angiopoetin-like 4 that enhances metastatic activity and correlates with increased breast 
cancer metastasis to the lungs. Angiopoetin-like 4 has the ability to disrupt endothelial cell-
cell junctions and thereby increases vessel permeability which enables tumor cells to 
intravasate as well as to exit the blood vessels at secondary sites (54). TGF-β is provided by 
TAMs, platelets and fibroblasts and is an important regulator of EMT in cancer cells (28,380-
382). Altogether, metastatic dissemination is initiated by phenotypic switching of tumor cells 
which is potently driven by pro-migratory and ECM remodeling factors provided by stromal 
cells (4,383,384).  
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4. Metastatic microenvironment 
Once a tumor cell reaches the circulation, intrinsic properties as well as exploiting host cells 
enable tumor cells to survive, firmly adhere to the vascular lining and eventually extravasate 
and colonize secondary sites. Beforehand, primary tumors elicit the release of signals such 
as cytokines and chemokines that direct host cells to distant organs. These host cells, 
especially bone marrow-derived myeloid cells, prepare a pre-metastatic niche providing a 
suitable and conductive environment for tumor cell engraftment (383,385).  
 
4.1 Pre-metastatic niche formation 
Several factors that are secreted by primary tumors can induce the clustering of specific cell 
populations such as hematopoietic progenitor cells and macrophages at future metastatic 
sites to create a permissive environment for tumor cell adhesion and extravasation (35,36). It 
 
Fig. 6. From primary tumor to metastasis. 
① Environmental stimuli such as hypoxia or cytokines induce EMT of tumor cells by activating various 
transcription factors leading to a motile tumor cell phenotype. ② Stromal immune cells including TAMs 
and CAFs strongly provide cancer cells with pro-tumorigenic proteases, cytokines and growth factors 
thereby supporting ECM remodeling and angiogenesis. ③ Tumor cells intravasate and form clots by 
associating with platelets and leukocytes. ④ This helps tumor cells to survive in circulation. ⑤ TME-
derived factors prime future secondary sites by inducing clusters of bone marrow-derived cells. ⑥ 
This pre-metastatic niche facilitates tumor cell extravasation and engraftment (Based on Quail et al., 
2013, Nature Medicine). 
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has been demonstrated that primary tumors upregulate fibronectin expression by residential 
fibroblasts at secondary organs, which attracts VEGF-receptor 1 positive (VEGFR1+) 
hematopoietic progenitor cells that cluster at future metastatic sites (35). By depleting 
VEGFR+ hematopoietic progenitor cells formation of pre-metastatic clusters can be 
decreased and metastasis blocked. VCAM-1+ cancer cells interact with the VLA-4 integrin 
expressed by macrophages during breast cancer metastasis, leading to the protection of 
tumor cells from caspase-induced apoptosis (386). Metastasis to the bone is mediated by 
VCAM-1+ tumor cell interactions with different integrin partners in osteoclasts (387). A 
hypoxic environment in breast cancer has been reported to induce the expression of lysyl 
odidase (LOX), which co-localizes with fibronectin at potential secondary sites and facilitates 
myeloid cell recruitment followed by tumor cell colonization in the lung. These myeloid cells 
are capable of degrading the basement membrane by MMP2 production and favored 
additional recruitment of myeloid cells (37,388). By inhibiting LOX in tumor cells myeloid cell 
attraction to the pre-metastatic niche was blocked and lung metastasis reduced (37). Other 
tumor-derived molecules that are involved while establishing a pre-metastatic niche include 
VEGF-A, TNF-α and TGF-β (36). These factors promote the expression of the inflammatory-
related proteins S100A8 and S100A9 that consequently induce the expression of the 
chemoattractant serum amyloid A3 which stimulates NF-κB signaling via the toll-like receptor 
4 (36,389). This pathway is responsible for the recruitment of both tumor cells and CD11b+ 
myeloid cells to the pre-metastatic niche (36,389). S100A8 and S100A9 expression in cancer 
patients correlates with poor prognosis (390). The tumor-derived factor CCL5 has also been 
shown to promote the release of S100A4. Thereby pro-inflammatory cytokine-producing T-
cells are attracted and subsequently leading to myeloid cell infiltration into the pre-metastatic 
environment (391,392). Hematogenic progenitor cells that accumulate at secondary sites 
revealed osteopontin expression, which has been associated with tumor cell adhesion and 
survival as well as with the regulation of MMP activity and host immune defense (393). G-
CSF has been shown to mobilize Ly6G+Ly6C+ granulocytes to organ-specific metastatic sites 
which resulted in enhanced metastasis of several tumors (394). Recently, primary tumor-
INTRODUCTION  
43 
derived exosomes were reported to shape their environment and generate a pro-tumoral 
niche, which attracts bone marrow derived progenitors that enhance metastatic 
dissemination (395,396). Exosomes are small biologically active vesicles that are derived 
from the late endosome and are involved in numerous extracellular activities such as cell 
signaling, immunological communication and cell recruitment (397). In conclusion, tumor cell 
specific traits and factors released by the TME mobilize and modify stromal cells, especially 
hematopoietic progenitor cells, to generate a fertile milieu at secondary organs which directs 
the establishment of secondary lesions (383,384,398).  
 
4.2 Leukocytes, chemokines and selectins shape the metastatic environment 
During the last 10 years research has generated knowledge about the concerted interplay 
between tumor cells, immune cells and chemottractants which support tumor cell adhesion 
and extravasation during metastasis. Selectins are considered to be adhesion molecules 
physically connecting the different players including tumor cells, endothelial cells, platelets 
and leukocytes. Therefore, selectins shape the metastatic environment and elicit further 
responses which facilitate tumor cell extravasation (Figure 7). 
  
 
The activated endothelium is characterized by the increased expression of adhesion 
molecules and chemokines and is a well-recognized regulator of metastasis. Tumor cells that 
 
Figure 7. Selectins shape the 
metastatic environment.  
P-, L-, and E-selectin mediate interactions 
between carcinoma cells, platelets, 
leukocytes and the activated 
endothelium. Thereby selectins modulate 
the capacity of cancer cells to adhere to 
and to transmigrate through the 
endothelium. 
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enter the liver microvasculature induce TNF-α production by residential macrophages as well 
as vascular adhesion receptors such as E-selectin, VCAM-1 and PECAM-1 which promoted 
tumor cell arrest, extravasation and liver metastasis (399,400). Experimental metastasis 
models also showed that by reducing endothelial activation, the metastatic burden in animal 
models can be lowered (78,401). One assumption is that the presence of E- and P-selectin 
or other adhesion molecules on the activated endothelium is critically involved in mediating 
tumor cell survival, adhesion or recruitment of immune cells. P- and L-selectin-mediated 
tumor cell interactions with platelets and neutrophils in the microvasculature trigger the 
activation of the endothelium, which in turn produces the chemokine CCL5 (43). CCL5-
mediated monocyte recruitment promotes tumor cell survival and metastasis (43).  
The recruitment of myeloid cells, especially inflammatory monocytes, is strongly associated 
with enhanced metastatic colonization (40,43,199,402-404). The recruitment of 
CD11b+CD68+F4/80+ macrophages by tumor cell clots mediated by tissue factor was shown 
to enhance the survival of arrested tumor cells during experimental lung metastasis (405). 
Tumor cell clot formation was also shown to induce the inflammatory marker VCAM-1 on the 
endothelium leading to myeloid cell recruitment, tumor cell survival and increased pulmonary 
metastasis (406). While there is compelling evidence for E-selectin as mediator of tumor cell 
adhesion to the microvasculature (see section 2.5.5) it remains to be elucidated whether E-
selectin also participates in the interplay with other components of the metastatic 
environment.  
Chemokines and chemokine receptors are strongly involved during the recruitment of 
immune cells to the metastatic environment and have been shown to support tumor cell 
extravasation. CCR1 was shown to control myeloid cell infiltration as well as angiogenesis 
thus promoting liver cancer metastasis in mice (407). CCR1+ myeloid cells that have been 
recruited to the site of metastasis produce MMP2 and MMP9 and probably facilitate 
metastatic colonization (408). The CCL2/CCR2 signaling axis has been identified as a 
prominent contributor to tumor cell extravasation and metastatic colonization. Elevated levels 
of CCL2 are clearly associated with poor prognosis in breast, colon, prostate and cervix 
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cancer patients (409-412). The activation of the CCL2/CCR2 axis or CCL2 overexpression in 
prostate cancer cells promoted and increased metastasis to the bone, which was associated 
with enhanced macrophage recruitment (413,414). Similarly to these findings, CCL2-
expressing breast cancer cells interact with CCR2+ stromal cells of monocytic origin to favor 
colonization in lungs and bone (402). One mechanism which promotes CCL2 expression by 
tumor cells is mediated via NF-κB activation in tumor cells due direct contact with platelets 
leading to monocyte recruitment (28). Further evidence supporting the role of CCL2 as a 
facilitator of lung metastasis comes from a study which showed that Gr1+CCR2+ 
inflammatory monocytes are preferentially recruited to pulmonary metastases through CCL2, 
derived from both tumor and stromal cells (40,42). These studies also linked increased 
extravasation, seeding and growth of tumor cells via VEGF-dependent mechanisms to CCL2 
signaling. CCL2 derived from colon carcinoma cells has been shown to directly signal to 
CCR2+ endothelial cells which results in increased vascular permeability via the JAK2-Stat5 
and p38 MAPK signaling pathways, consequently enabling tumor cell extravasation (403). A 
distinct population of CD11b/Gr1(mid) cells has been observed to strongly accumulate during 
the establishment of liver metastases due to tumor-derived CCL2 mediated recruitment from 
the bone marrow (415).  
It is currently unknown whether the chemokine/chemokine receptor signaling axis directly 
impacts the expression of selectins or vice versa. CCL2/CCR2 signaling in endothelial cells 
engages the p38 MAPK signaling pathway (403), which is also involved in E- and P-selectin 
up-regulation during lung colonization (401). P- and L-selectin-mediated interactions led to 
the expression of CCL5 by endothelial cells (43) whereas the underlying mechanism is not 
defined. Nevertheless, this implies a link between the chemokine/chemokine receptor axis 
and selectin expression in the metastatic microenvironment.  
The importance of selectin-ligand interactions within the metastatic environment has been 
recently highlighted by showing that selectin ligands on monocytes, especially PSGL-1, are 
crucial for monocyte recruitment to metastasizing tumor cells and enable efficient tumor cell 
survival, extravasation and metastasis (404). Thus, communication between tumor cells, the 
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endothelium and leukocytes are regulated by chemokines and mediated by selectins, which 
both substantially shape the metastatic niche. Our knowledge about this complex 
cooperation is incomplete and it requires profound research that will open new possibilities 
for therapeutic interventions.  
 
4.3 Selectins and selectin ligands as therapeutic targets 
Most anti-cancer therapies are designed to reduce the growth of primary tumors however 
therapeutic strategies, which aim to successfully prevent establishment of secondary lesions 
would provide a great alternative tool to improve the long term survival of cancer patients. It 
is important to emphasize that the time point of anti-metastatic drug administration might be 
crucial and often not optimal since metastatic events often precede the clinical diagnosis of 
malignancy. There have already been several attempts to interfere with the diverse selectin- 
and selectin ligand-mediated interactions during metastasis, but so far none of the potential 
candidates has been tested for clinical trials. 
For the treatment of inflammatory diseases including psoriasis, graft-versus-host-disease, 
arthritis, asthma, atherosclerosis and ischemia-reperfusion injury, several anti-selectin 
therapies have been developed (416,417). Although experimental animal models have 
revealed promising effects, clinical trials have mostly been unsuccessful. One example is an 
engineered human anti-E-selectin antibody which showed protective effects in skin-versus 
graft disease in SCID mice by reducing leukocyte recruitment. However, the treatment failed 
to improve symptoms of psoriasis patients (418,419). By competitively inhibiting the 
interactions between selectins and their ligands with a recombinant soluble PSGL-1 
immunoglobulin chimera (human PSGL-1 fused to a modified hinge region of human IgG1), 
leukocyte rolling and inflammation was prevented in vivo but this treatment was discontinued 
due to high production costs (416,417). Biamosiamose is a pan-selectin antagonist and 
revealed clinical improvement upon administration to psoriasis patients due to reduced 
leukocyte extravasation (420). Several other sLex mimetics such as cylexine or Efomycine M 
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have been tested in animal models of ischemia-reperfusion injury, psoriasis or asthma and 
have been evaluated to a certain extent in clinical trials (149,416,421,422). 
Only a few studies have used such strategies to directly target selectins for anti-cancer 
treatments. In animal models anti-P-selectin monoclonal antibodies have been reported to 
suppress metastasis of gastric cancer with no adverse effects on immune functions (423). 
There have been attempts to inhibit the production of selectin ligands in cancer cells by using 
glycometabolic inhibitors which target the O-linked glycosylation of mucins or the activity of 
fucosyltransferases (421) shown to be involved during metastasis in vivo (424,425). 
Unfractionated and low molecular weight heparin exhibit metastasis suppressing effects in 
experimental mouse models probably by inhibiting P- and L-selectin-mediated interactions 
with tumor cells (426-428). Heparin is commonly used as an anticoagulant in the clinic and 
has been prescribed for treating cancer-associated thromboembolisms (Trousseau 
syndrome) (429,430). Its beneficial effects on the survival of patients (431) are most probably 
not only a consequence of anti-thrombotic activity but also due to selectins which are a major 
target of heparin (428).  
Taken together, blocking selectins and their ligands to interrupt the metastatic cascade 
provides attractive prospects for treating cancer and thus, better knowledge of selectin-
mediated communication within the metastatic microenvironment is essential. 
 
5. Scientific aim 
E-selectin is a well-studied facilitator of metastasis and historically considered to mediate 
intravascular tumor cell attachment. Interestingly, experimental data suggests that E-selectin 
is dispensable for tumor cell lodging in the microvasculature. In the present study we aimed 
to elucidate the role of E-selectin in metastasis by evaluating the interplay between E-
selectin and the metastatic microenvironment during early metastatic phases. Identification of 
mechanisms how E-selectin interacts with different components of the metastatic niche may 
help to develop new approaches to therapeutically prevent metastasis.    
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Key point 1: Tumor cell-induced endothelial activation induces E-selectin expression that 
promotes monocyte recruitment resulting in increased CCL2 levels during metastasis. 
 
Key point 2: E-selectin-dependent monocyte interaction with the endothelium induces 
retraction of endothelial cells and thereby promotes tumor cell extravasation. 
 
Abstract 
During hematogenous metastasis tumor cells interact with blood constituents and these 
contacts enhance the capacity to colonize distant organs. Selectins are vascular cell 
adhesion receptors that contribute to the formation of a metastatic microenvironment but the 
role of endothelial E-selectin remains to be clarified. Here we show that E-selectin is a major 
adhesion receptor for the recruitment of monocytes to metastatic tumor cells. Experimental 
and spontaneous lung metastasis using murine tumor cells without E-selectin ligands (MC-
38, B16-BL6 and LLC) was attenuated in E-selectin deficient mice. These findings provide 
evidence that E-selectin modulates metastasis also independently of a direct interaction with 
tumor cells. E-selectin-dependent myeloid cell recruitment further correlated with the 
accumulation of CCL2 chemokine in the metastatic lungs. E-selectin-mediated activation of 
both endothelial cells and monocytes contributed to enhanced CCL2 expression in the 
metastatic tissue. Monocytes supported tumor cell trans-endothelial migration which was 
dependent on E-selectin interaction with ligands on monocytes and resulted in an increased 
endothelial retraction. Accordingly, tumor cell-induced increase in lung vascular permeability 
was reduced in the absence of E-selectin. Thus, endothelial E-selectin expression during 
cancer progression shapes the tumor microenvironment through the recruitment, adhesion 
and activation of leukocytes that facilitate tumor cell extravasation and thereby metastasis. 
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Introduction 
Hematogenous metastasis is a multistep process in which diverse interactions between 
tumor cells and their microenvironment allow the cells to cross physical boundaries, 
disseminate and colonize distant organs. Specifically, cell-cell interactions between tumor 
cells and blood constituents, such as platelets, leukocytes and endothelial cells, are initially 
mediated by selectins at different steps of the metastatic cascade (1-4). 
Selectins are vascular cell adhesion receptors which are responsible for initial rolling and 
attachment of leukocytes to the endothelium and thereby enabling leukocyte trafficking and 
homeostasis (2,5). The selectin family consists of three members: E-, L-, and P-selectin 
which are present on activated endothelium, leukocytes or activated platelets and 
endothelium, respectively. Selectins recognize sialylated and fucosylated lactosamine 
terminal structures (called sialyl-Lewis antigens) displayed on leukocytes, platelets, and the 
endothelium or tumor cells. It is accepted that malignant transformation is associated with 
altered or excessive carbohydrate structure presentation on tumor cells, which correlates 
with poor prognosis due to metastasis (3,6). 
E-selectin is the major leukocyte adhesion receptor that is present only on endothelial cells 
upon endothelial activation and requires de novo expression. E-selectin has been 
investigated as the primary receptor mediating tumor cell metastasis through facilitating 
adhesion of tumor cells on the endothelium (1). Several studies demonstrate that tumor cells 
expressing selectin ligands adhere to activated endothelium under flow conditions in vitro 
(7,8). There is also experimental evidence that E-selectin was up-regulated during metastatic 
liver colonization (9,10). E-selectin expression was observed in the microenvironment of 
tumor cells several hours after their lodging, indicating an inflammatory-like endothelial 
activation (11-13). Recently, E-selectin expression in the pre-metastatic lungs correlated with 
increased tumor cell homing to these tissues and with enhanced recruitment of myeloid cells 
(14). However, there is accumulating evidence that selectins contribute to stromal cell 
organization in the metastatic microenvironment (15,16). Accordingly, E-selectin is not 
required for tumor cell lodging in the microvasculature since endothelial E-selectin 
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expression is first induced after tumor cells are already present in the lungs (12). Thus the 
mechanism of E-selectin contribution to cancer progression requires further investigations in 
vivo. 
Enhanced metastatic colonization of distant tissues is associated with increased recruitment 
of inflammatory, especially myeloid, cells (11,16-19). Among several chemokines potentially 
involved in metastasis, CCL2 appears to be the major chemokine involved in shaping up of 
the metastatic microenvironment primarily associated with the recruitment of monocytic cells. 
Interference in CCL2-CCR2 axis resulted in attenuation of metastasis of breast, lung, and 
colon tumor cells in various mouse models (18-21).  
Considering the enhanced E-selectin expression upon tumor cell injection in variety of animal 
models, the role of E-selectin as a mediator of leukocyte recruitment can be expected.  The 
presents study aims to elucidate the role of E-selectin in metastasis focusing on all 
participating cells which goes beyond a direct tumor cell binding to endothelial E-selectin.  
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Materials and Methods 
Cell culture 
Mouse colon carcinoma cell line MC-38 stably expressing GFP (MC-38GFP), Lewis lung 
carcinoma (LLC1; ATCC) and B16-BL6 melanoma cells were grown in DMEM medium with 
10% FCS (19,22). Lewis lung carcinoma cells (3LL) were grown in RPMI medium with 10% 
FCS (12).  
Mice 
Animals were maintained under specific pathogen-free conditions, and experiments were 
according to the guidelines of the Swiss Animal Protection Law, and approved by Veterinary 
Office of Kanton Zurich. C57BL/6, Ccl2 deficient (Ccl2-/-) and E-selectin deficient mice (E-sel-
/-) were purchased from The Jackson Laboratory. Fucosyltransferase 7 deficient mice (Fuc-
TVII-/-) were kindly provided by Dr. J.B. Lowe (University of Michigan, Ann Arbor, MI). 
Experimental lung metastasis 
MC-38GFP cells (300’000 cells) were intravenously injected (i.v.) into the tail vein of a mouse 
and metastatic foci were analyzed on day 28. 3LL and B16-BL6 cells (150’000 cells) were i.v. 
injected into mice and lungs were analyzed on day 14.  
Spontaneous lung metastasis 
LLC cells (200’000 cells) were subcutaneously injected into the right flank of mice and 
primary tumors were removed 18 days later when tumors reached a size of approx. 1 cm in 
diameter. Mice were terminated at day 30 and metastatic foci were counted on perfused 
lungs. Paraffin sections (5 μm) were stained with hematoxylin and eosin (Sigma-Aldrich), 
scanned with a Mirax Midi Slide Scanner (Zeiss) and analyzed with the Panoramic viewer 
1.15.2 software (3DHISTECH).  
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Flow cytometry analysis 
Mouse lungs perfused with PBS were minced and digested with Collagenase D and A (2 
mg/mL each, Roche) for 1 hour at 37°C while shaking. Cells were separated using 18Gx1½ 
syringes and 40 μm cell strainers and erythrocytes were lysed using PharmLyse (BD 
Biosciences). Cells were incubated with anti-mouse CD16/32 mAb (eBioscience) and stained 
with fluorophore-conjugated antibodies against CD45, CD11b, F4/80, Ly6G, Ly6C and CD31 
(BD Biosciences). Blood samples were treated with PharmLyse (BD Biosciences) and 
stained as described above. Data were acquired on a FACS Canto II (BD Biosciences) and 
analyzed using Flow Jo software (Tree Star). 
Analysis of leukocytes, tumor cells and selectins in lung tissue 
Frozen tissues were embedded in OCT (Sakura) as described previously (15). Cryosections 
(6 μm) were stained with following antibodies: CD11b; CD11b-biotin; Ly6G (BD Biosciences), 
F4/80 (AbD Serotec); and CD62E (BD Biosciences). Alexa568 conjugated anti-rat IgG or 
Alexa647-conjugated Streptavidin (Life Technologies) were used for detection using 
fluorescence microscope (Zeiss). Tumor cells and leukocytes were counted and the 
percentage of tumor cells associated with leukocytes was determined. The analysis of 
selectin and myeloid cell detection in lung sections was performed with a SP5 confocal 
microscope (Leica). Images were acquired of a total of 5 μm stacks and analyzed with Imaris 
Software (Bitplane).  
Isolation of primary pulmonary endothelial cells 
Pulmonary endothelial cells were isolated using a positive immuno-magnetic selection as 
described previously (19). Isolated endothelial cells were cultured in gelatin-coated 6-well 
plates in medium containing endothelial cell growth supplement (BD Biosciences). 
Isolation of bone marrow monocytes 
Femur, tibia and pelvic bones were harvested from mice and crushed in PBS containing 2% 
FCS and 2.5mM EDTA. Red blood cells were lysed using ammonium chloride solution. Bone 
marrow derived monocytes were enriched by magnetic activated cell sorting (MACS) using 
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biotinylated macrophage colony-stimulating factor receptor (M-CSFR, CD115) antibody 
(Biolegend) and streptavidin-conjugated magnetic beads (Miltenyi Biotec).  
Monocyte recruitment in a microfluidic channel system 
Primary lung microvascular cells (175’000 cells) were plated on gelatin-coated µ-Slide I0.2 
Luer (ibidi GmbH) and were allowed to grow to confluence for 2 days. The endothelial 
monolayer was manually perfused five times with 200’000 MC-38GFP cells in 100μl media. 
After 4 hours slides were perfused with CellTrace calcein red-orange, AM (Life Technologies) 
stained bone marrow monocytes (2x106 cells/ml) in HEPES buffered Ringer solution 
supplemented with 25% washed red blood cells. Perfusion of slides was performed using an 
ibidi air pressure pump system (ibidi) applying a flow rate of 2 dyne/cm2. Mosaic images of 
slides were acquired using an inverted fluorescence microscope (Zeiss Axio Observer Z.1) at 
indicated time points. Pictures were analyzed with ZEN software (Zeiss).  
Vascular permeability assay 
Vascular permeability in the lungs was determined with Evans blue dye extravasation 
technique (19). Briefly, 24 hours after mice were injected with tumor cells 2 mg of Evans blue 
was injected i.v. followed by euthanasia 30 min later. Extracted Evans blue was measured 
using spectrophotometer (620 nm). Clodronate liposomes (1.8 mg) were i.v. injected to 
deplete monocytes (23) 24 hours prior to tumor cell i.v. injection, followed by Evans blue 
injection 24 hours later.  
RNA isolation and quantitative real-time PCR 
Perfused and snap frozen lungs of mice were used for a total RNA isolation using TRI 
Reagent (Sigma-Aldrich) according to the manufacturer’s protocol. The quantity and quality 
of the RNA was determined spectroscopically using a Nanodrop (Thermo Scientific). Isolated 
RNA was reversely transcribed into cDNA using Omniscript RT Kit (Qiagen) according to the 
manufacturer’s protocol. Real-time PCR was performed using SYBR Green JumpStart Taq 
ReadyMix (Sigma-Aldrich) in combination with the MX300P light cycler (Agilent). Data were 
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analyzed using MxPro Mx300P software (Agilent) and normalized to the housekeeping gene 
Gapdh. Primers separated by an intron were used (Table S1). 
RNA isolation from sorted pulmonary monocytes and endothelial cells 
PBS-perfused lungs were minced and digested in Collagenase D and A (2 mg/mL each, 
Roche) for 1 hour at 37°C. A single-cell suspension was prepared by passing the digested 
lungs through 18Gx1½ syringes, 100μm and 40μm cell strainers (BD Biosciences). Cells 
were incubated with rat antibodies against CD31, CD45, CD11b, Ly6C and Ly6G 
(eBiosciences). Endothelial cells were sorted as CD45-CD11b-CD31+ cells and inflammatory 
monocytes were sorted as CD45+CD11b+Ly6ChighLy6G- cells with a FACSAria III sorter (BD 
Biosciences). Total RNA of sorted cells was isolated using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s protocol. Real-time PCR was performed as described above. 
Cytometric bead array 
Perfused lungs of mice were homogenized, supernatant was collected and concentration of 
the chemokine CCL2 was assessed by using the cytometric bead array Kit for mouse CCL2 
(BD Biosciences) according to the manufacturer’s protocol. CCL2 levels were normalized to 
the total protein amount of lung supernatants.  
Trans-endothelial migration assay 
Primary lung endothelial cells (25’000) were seeded on gelatin coated 24-well transwell 
inserts (8μm pores; BD Biosciences) and allowed to grow to confluence for 2 days. MC-
38GFP cells (25’000) were seeded into transwell inserts with or without monocytes (200’000) 
purified from bone marrow (untreated or fixed) in 3% FCS/RPMI in the upper chamber and 
10% FCS/RPMI was added into the lower chamber. When fixed monocytes were used, cells 
were fixed with 2% PFA for 12 minutes at 4°C and washed prior to use. After 16 hours of co-
culture, the upper side of the insert was scraped off, the insert was fixed in 2% PFA and 
nuclei were stained with DAPI. Tumor cells on the lower side of the membrane were 
analyzed with a fluorescence microscope (Zeiss).  
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Staining of endothelial cytoskeleton 
Endothelial F-actin was detected with Phalloidin staining (24). Briefly, 40’000 pulmonary 
endothelial cells grown on gelatin-coated chamber slides for 36 hours were co-incubated with 
MC-38GFP cells (40’000) stained with a PKH26 red fluorescent dye (Sigma-Aldrich) and 
bone marrow monocytes (200’000 cells) for 8 hours. Cells were fixed with 2% PFA, 
permeabilized (0.1% saponin), and stained with Phalloidin-FITC (6.67 mg/ml, Sigma-Aldrich). 
Nuclei were stained with DAPI and cells were mounted in ProLong Gold (Life technologies).  
Statistical analysis 
Statistical analysis was performed with the GraphPad Prism software (version 5.01). All data 
are presented as mean ±SEM and were analyzed by ANOVA with the post-hoc Bonferroni 
multiple comparison test. Analysis of two samples was performed with Mann-Whitney test 
unless stated otherwise. 
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Results 
E-selectin facilitates experimental metastasis of tumor cells with no E-selectin ligands  
During cancer progression it has been postulated that E-selectin binding to tumor cells 
facilitates tumor cell lodging in the microvasculature and thereby metastasis (1,25). To 
assess whether a direct interaction of tumor cells with E-selectin is required for metastasis, 
we tested mouse adenocarcinoma cells (MC-38GFP) in an experimental metastasis model. 
MC-38GFP cells were confirmed to express no E-selectin ligands while P- and L-selectin 
ligands were present (Figure S1A). Intravenous injection (i.v.) of MC-38GFP into C57BL/6 
(wt) and E-selectin deficient (E-sel-/-) mice revealed a significant reduction in the number of 
pulmonary metastatic foci and total tumor burden in E-sel-/- mice compared to C57BL/6 mice 
(Figure 1A-B, S1B). To confirm that this finding is not cell line specific we used Lewis lung 
carcinoma cells (3LL) and melanoma cells (B16-BL6) in the same experimental model 
(Figure 1C-F). Both 3LL and B16-BL6 cells do not express any E-selectin ligands (Figure 
S1A). We observed reduced metastasis in E-sel-/- mice with both cell lines (Figure 1C-F). 
Since E-selectin is expressed only upon endothelial activation and the fact that in 
experimental metastasis model tumor cells are present in the lungs prior to this point (12), 
these data strongly indicate that E-selectin promotes metastasis without directly interacting 
with tumor cells but through interaction with other cells within the tumor microenvironment.  
E-selectin-dependent leukocyte infiltration of the metastatic tissue - lungs 
Leukocytes constitute a crucial part of the metastatic microenvironment supporting tumor cell 
extravasation (16-19). To assess whether E-selectin facilitates metastasis through 
recruitment of leukocytes, we analyzed the early metastatic microenvironment in the lungs of 
mice. Tumor cell-injected mice were terminated 24 and 48 hours later and perfused lungs 
were analyzed by flow cytometry. Total leukocyte infiltration was significantly increased in 
C57BL/6 mice 48 h post-tumor cell injection (p.i.) but remained unchanged in E-sel-/- mice 
(Figure 2A). Further analysis revealed significant increase in the number of inflammatory 
monocytes (Ly6Chigh) and macrophages (F4/80+) in C57BL/6 mice compared to E-sel-/- mice 
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(Figure 2B-C). However, no difference was found in granulocyte (Ly6G+) infiltration to lungs 
of mice at these time points (data not shown). We further analyzed the number of leukocytes 
and tumor cells on lung cryosections. Reduced numbers of macrophages (F4/80+) were 
found at 16 and 24 hours p.i. in E-sel-/- mice compared to C57BL/6 mice (Figure 2D and F). 
We observed more granulocytes (Ly6G+) only at 16 hours p.i. in C57BL/6 compared to E-sel-
/- mice (Figure 2E and F). The parallel analysis of peripheral blood cells from naïve mice 
revealed no difference in numbers of CD11b+, F4/80+, and Ly6G+ cells between E-sel-/- and 
C57BL/6 mice (Figure S2D). Thus, the missing monocyte infiltration in E-sel-/- mice indicates 
that E-selectin expression is critical for the leukocyte recruitment to the metastatic 
organ/lungs.  
To assess the role of E-selectin-dependent leukocyte recruitment on tumor cell survival, we 
quantified the number of tumor cells in the lungs of mice 16 and 24 hours p.i. Significantly 
decreased number of viable (GFP-positive) tumor cells in the lungs of E-sel-/- mice was 
observed at both time points indicating an impairment of early metastatic events (Figure 2G).  
Tumor cell-induced E-selectin expression facilitates leukocyte recruitment to 
metastatic cells  
The observed difference in leukocyte infiltration to the lungs indicates that E-selectin is 
present during early phase of metastasis. We analyzed E-selectin expression in the lungs 
upon tumor cell injection at different time points by real-time PCR. Maximal E-selectin 
expression was observed 6 hours p.i. which was reduced almost to baseline levels 12 hours 
p.i. (Figure 3A). Next we detected E-selectin in the vicinity of tumor cells 6 and 14 hours p.i. 
in C57BL/6 mice using immunofluorescence microscopy (Figure 3B). Importantly, myeloid 
cells (CD11b+) were detected in the areas positive for E-selectin, which was always in the 
vicinity of tumor cells (Figure 3C). To assess whether E-selectin facilitates leukocyte 
recruitment to metastatic tumor cells we analyzed the interaction between tumor cells and 
leukocytes on lung sections. A significant reduction in both F4/80+ cell and Ly6G+ cell 
interactions was detected at 16 hours p.i. in E-sel-/- mice compared to C57BL/6 mice (Figure 
3D). However, only F4/80+ cell interactions remained significantly different also 24 hours p.i.  
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To test whether E-selectin is indeed involved in leukocyte recruitment to metastasizing tumor 
cells in the microvasculature we analyzed this process using a microfluidic system in vitro 
(Figure S3). We assessed monocyte recruitment to MC-38GFP cells adherent on primary 
lung endothelial monolayers derived from C57BL/6 and E-sel-/- mice under physiological 
post-capillary flow conditions. Reduced number of monocytes was bound to endothelial cells 
around attached tumor cells on E-sel-/- derived endothelial monolayers compared to 
C57BL/6-derived endothelial monolayers (Figure 3E-F). We observed reduced monocyte 
adhesion already at 15 min after initiation of the perfusion and this effect lasted for at least 90 
minutes. In addition, the number of monocytes present within the vicinity of a tumor cell was 
also significantly reduced on endothelial monolayers derived from E-sel-/- mice (Figure 3G). 
Given the absence of E-selectin ligands and therefore the inability of MC-38GFP cells to 
interact with the E-selectin, these in vivo and in vitro data provide evidence that E-selectin 
facilitates monocyte recruitment to metastasizing tumor cells.  
Intravascular tumor cells induce endothelial activation and E-selectin contributes to 
an increased CCL2 pool in metastatic lungs 
E-selectin expression is an established marker of endothelial activation that is observed both 
in inflammatory and cancer-related situations (2,5). Next, we analyzed the activation status of 
the lung endothelium in response to tumor cell injection. Expression levels of vascular 
adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1) were 
increased upon tumor cell injection in lungs of C57BL/6 mice but remained unchanged in 
lungs of E-sel-/- mice 6 and 12 hours p.i. compared to naïve mice (Figure 4A-B). In addition, 
we observed significant increase in expression of chemokine CCL2 and its receptor CCR2 in 
the lungs of C57BL/6 mice 6, 12 and 24 hours p.i., while only a minimal increase in CCL2, 
but not CCR2 in E-sel-/- mice could be detected (Figure 4C and D). CCL2 is produced both 
by MC-38GFP cells and by stromal cells and the CCL2/CCR2 signaling axis has been 
associated with recruitment of inflammatory monocytes, vascular permeability and tumor cell 
extravasation (17-19). The reduced CCL2 expression levels in E-sel-/- mice 12 and 24 hours 
p.i. can be explained by the reduced numbers of leukocytes or tumor cells in the 
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microvasculature of the lungs (Figure 2D-G). However, comparable number of tumor cells 
and leukocytes are present in C57BL/6 and E-sel-/- mice 6 hours p.i., respectively (data not 
shown). This observation indicates that high CCL2 expression results from endogenous 
upregulation by endothelial or myeloid cells, that is dependent on E-selectin.   
Next we assessed the role of CCL2 from tumor cells on the metastatic microenvironment by 
injection of MC-38GFP cells with a silenced CCL2 expression by 50% (MC-38GFP CCL2 
KD) and compared with wild type MC-38GFP cells 6 hours p.i. (Figure S4A). We observed 
significantly reduced endothelial activation in mice injected with MC-38GFP CCL2 KD as 
measured by E-selectin and VCAM-1 expression; and similarly reduced CCL2 and CCR2 
expression (Figure 4E-G and S4B). These results indicate that the reduced CCL2 expression 
by tumor cells resulted in impaired endothelial activation indicating a possible direct 
involvement of tumor cell-derived CCL2 in endothelial activation and thereby the expression 
of E-selectin required for leukocyte recruitment.  
To test how tumor cell injection changes the CCL2 levels within the metastatic lungs, we 
analyzed CCL2 protein concentrations in C57BL/6, E-sel-/-, and Ccl2-deficient mice (Ccl2-/-) 6 
and 12 hours p.i. Compared to untreated mice (3 pg) CCL2 protein levels were significantly 
elevated in C57BL/6 mice (27 pg) while a diminished increased in lungs of E-sel-/- mice (11 
pg) was detected 6 hours p.i. (Figure 4H). In lungs of Ccl2-/-mice we observed minimal 
amounts of CCL2 (2 pg), which reflected the tumor-derived CCL2. The concentration of 
CCL2 remained high in the lungs of C57BL/6 mice also 12 hours p.i., albeit slightly 
decreased (Figure 4I). Thus, the strong increase in CCL2 in tumor cell-injected C57BL/6 
mice showed that the majority of CCL2 is derived from the local microenvironment. 
Furthermore, the significant reduction of CCL2 pool in E-sel-/- mice strongly argues for the E-
selectin involvement in chemokine production. To address the source of CCL2 production in 
metastatic tissue, we sorted endothelial cells (CD31+) and myeloid cells (CD11b+/Ly6Chigh) 
from lungs of mice 12 hours p.i. and analyzed CCL2 expression. We observed significant 
increase in CCL2 expression in endothelial cells from C57BL/6 compared to naïve mice or E-
sel-/- mice (Figure 4J). Interestingly, CCL2 expression was also increased in sorted 
RESULTS  
79 
monocytes only from C57BL/6 mice, indicating that E-selectin-mediated activation of 
monocytes induces CCL2 expression. Indeed, the absolute CCL2 expression levels were 
mostly derived from monocytes (Figure S4C). These data provided evidence that CCL2 
expression is induced by E-selectin-mediated activation of both endothelial cells and 
monocytes, which together contribute to the increased chemokine pool observed in the 
metastatic lungs. 
E-selectin-dependent activation of endothelial cells through selectin ligands on 
monocytes promotes tumor cell trans-endothelial migration 
Increased levels of CCL2 correlate with metastatic progression in various mouse models, 
and contribute to tumor cell extravasation (18-20,26). To test whether E-selectin expression 
is required for tumor cell extravasation, we analyzed lung vascular permeability 24 hours p.i. 
using the Evans blue assay (19). Tumor cell injection induced lung vascular permeability in 
C57BL/6 mice but was almost entirely absent in E-sel-/- mice (Figure 5A-B). Next we tested 
the hypothesis that the E-selectin-mediated recruitment and activation of monocytes 
contribute to induction of vascular permeability. We used clodronate liposome injection 
protocol to deplete peripheral circulating monocytes (F4/80+), followed 24 hours later by 
intravenous injection of MC-38GFP cells. Evans blue assay was performed 24 hours p.i. 
Monocyte-depleted C57BL/6 mice showed significantly decreased vascular permeability 
compared to untreated mice (Figure 5C-D). These data provided evidence that monocyte 
recruitment facilitates tumor cell extravasation by E-selectin-mediated leukocyte-dependent 
endothelial activation leading to increased vascular permeability. 
To further explore the role of E-selectin by tumor cell extravasation, we studied the capacity 
of tumor cells to transmigrate through endothelial cells in presence of monocytes (Figure S5). 
We used lung microvascular endothelial cell monolayers derived from C57BL/6 and E-sel-/- 
mice and studied the transmigration of MC-38GFP cells in the presence of monocytes 
(CD115+) (Figure 5E-F). While tumor cells have an intrinsic ability to migrate through 
endothelial cells, the presence of monocytes significantly promoted this process (19). 
However, there was no increase in tumor cell transmigration through E-selectin deficient 
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endothelial cells in presence of monocytes (Figure 5E-F). This observation suggests that E-
selectin binding to monocytes is essential for trans-endothelial migration. To test this 
hypothesis, we used fixed monocytes, which only present ligands on their surfaces, in the 
transmigration assay using endothelial cells from C57BL/6 mice (Figure 5G). Notably, fixed 
monocytes increased the tumor cell transmigration albeit not to the same level as unfixed 
cells. Next we used monocytes derived from fucosyltransferase-7 deficient mice (Fuc-TVII-/-), 
which lack most of E-selectin ligands (16). While Fuc-TVII-/- monocytes only partially 
promoted tumor cell transmigration, fixed Fuc-TVII-/- monocytes showed no effect (Figure 
5G). These observations strongly indicate that the interaction between endothelial E-selectin 
and selectin ligands on monocytes support tumor cell transmigration, while soluble factors 
from monocytes further promote this process. 
Tumor cell- and monocyte-induced endothelial cell retraction is E-selectin dependent  
Activation of selectins by ligand-binding or antibody crosslinking is known to trigger “outside-
in” signaling in endothelial cells and leukocytes, which induces migration of leukocytes 
through the endothelial cells (27,28). To elucidate the mechanism how monocyte-E-selectin 
interaction contributes to tumor cell transmigration we analyzed the cytoskeletal retraction of 
endothelial cells after 8 hours of co-culture with tumor cells with or without monocytes. Tumor 
cells or monocytes alone only slightly increased retraction of lung endothelial cells isolated 
from C57BL/6 mice as determined by Phalloidin-FITC staining (Figure 6A and C, D). The 
combination of tumor cells with monocytes strongly increased the number of retracting 
endothelial cells. However, we observed no cytoskeletal rearrangements in E-selectin 
deficient endothelial cells after co-culture with tumor cells or monocytes alone; nor with the 
combination of both cells (Figure 6B and D). These results support the conclusion that E-
selectin-dependent endothelial activation mediated by selectin ligands on monocytes 
promotes endothelial transmigration of tumor cells.  
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E-selectin facilitates spontaneous lung metastasis of tumor cells without E-selectin 
ligands 
We validated the role of E-selectin as facilitator of metastasis in a more clinically relevant 
model using a spontaneous lung metastasis assay using Lewis Lung carcinoma cells (LLC1) 
injected subcutaneously in a mouse flank. No major differences were observed in the primary 
tumor growth (data not shown). However, lung metastasis was significantly decreased in E-
sel-/- mice compared to C57BL/6 mice (Figure 7A-B), further supporting the essential role of 
E-selectin in formation of pre-metastatic niche and thereby metastasis. 
  
RESULTS  
82 
Discussion 
The cross-talk between tumor cells and their host environment is essential in all steps of the 
metastatic cascade (4). Metastatic tumors often express aberrant glycan structures that are 
potential ligands for vascular selectins (1,3). E-selectin has been previously studied only as a 
direct receptor for tumor cell-endothelial adhesion (12,29). However, initial arrest of tumor 
cells is also likely caused by physical constrictions in small capillaries and therefore 
independent of active adhesion (30). This raised the question whether E-selectin affects the 
metastatic cascade by other means than via a direct tumor cell adhesion to the endothelium. 
Since we used tumor cells without endogenous E-selectin ligands, a direct tumor cell binding 
to E-selectin and thereby endothelial adhesion could be excluded. The observed reduction of 
both monocyte recruitment and engagement with tumor cells in the lungs of E-sel-/- mice 
support the role of E-selectin as a mediator of host cell interactions within the tumor 
microenvironment. 
Markers of endothelial activation and inflammation are often up-regulated during the initial 
hours of intravascular tumor cell arrest in experimental metastasis models both in lungs and 
liver metastasis (12,29,31,32). Conversely reduction of endothelial activation diminished 
myeloid cell recruitment, tumor cell survival and metastasis (32-34). In line with these 
observations, we detected up-regulation of E-selectin, shortly after tumor cell arrest in the 
lung vasculature. While increased levels of endothelial activation markers VCAM-1 and 
ICAM-1 where detected in lungs of C57BL/6 mice no alterations of these adhesion molecules 
were detected in the lungs of E-sel-/- mice. Tumor cell-derived factors such as cytokines and 
chemokines together with physical factors like shear forces may trigger endothelial 
expression of E-selectin (31). We show that the tumor cell-derived chemokine CCL2 partially 
regulates vascular E-selectin induction by demonstrating that tumor cells with reduced CCL2 
expression elicit weaker E-selectin expression. Chemokine production has been linked to E-
selectin expression only in few studies in inflammatory models (35,36). In an atherosclerotic 
rat model the expression of CCL2 and adhesion molecules including E-selectin were up-
regulated on the endothelium and associated with monocyte recruitment (35). The inhibition 
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of p38 MAPKs in TNF-α stimulated-endothelial cells resulted in reduced E-selectin and 
chemokine expression including CCL2, IL-8, and IL-6 (36). Rapid cytokine production (e.g. 
IL-1) was observed in an experimental liver metastasis model one hour after intra-splenic 
injection of Lewis lung carcinoma subline H-59 (29). We observed that tumor cell-induced 
endothelial activation additionally up-regulates CCL2 expression by endothelial cells and 
monocytes and thereby contributes to metastasis (Figure 7C).  
CCL2 is a potent regulator of monocyte recruitment to metastasizing tumor cells and 
increased CCL2 levels at metastatic sites strongly correlate with metastasis (18-20). 
Furthermore, tumor cell-derived CCL2 activation of endothelial CCR2 induced vascular 
permeability and thereby assisting tumor cell extravasation (19). In this study, we observed 
decreased expression of CCL2 and CCR2 in lungs of E-sel-/- mice compared to C57BL/6 
mice. We identified both monocytes and endothelial cells as the major source of CCL2 in the 
activated metastatic environment. These findings are in line with previous observations that 
stromal-derived CCL2 contributes to metastasis (18,20,21). Whether CCL2 induced 
endothelial activation is directly linked to E-selectin expression requires further investigation. 
Practically unaffected CCL2 expression in monocytes isolated from lungs of E-sel-/- mice 
might be a result of lacking activation. Previously it was reported that monocyte-HUVEC 
interactions resulted in increased expression of CCL2 and IL-8, suggesting that leukocyte 
adhesion to endothelial cells causes their activation and subsequent increase in chemokine 
production (37). Our results suggest that E-selectin is the initiator of endothelial activation 
which is substantial for myeloid cell-derived CCL2 secretion within the developing metastatic 
niche (Figure 7C).  
Recruitment and activation of immune cells, especially inflammatory monocytes are strongly 
associated with enhanced metastatic colonization. Monocyte-secreted factors such as 
cytokines and chemokines assist intravascular tumor cells to survive and to extravasate from 
the circulation (11,15-19). We observed less recruitment of myeloid cells including 
macrophages, inflammatory monocytes and granulocytes to metastatic sites in lungs of E-sel-
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/- mice. The absence of E-selectin in combination with reduced CCL2 levels is likely impeding 
efficient capturing and firm adhesion of recruited monocytes.  
Previous studies revealed that selectin-mediated leukocyte interactions strongly support 
metastasis during early stages (15,16,22). This work provided evidence that enhanced 
monocyte-assisted tumor cell transmigration is dependent on endothelial E-selectin 
expression and on selectin ligands presented by monocytes. The finding that fixed 
monocytes displaying only selectin ligands on their surfaces were able to induce trans-
endothelial migration of tumor cells, strongly indicates that E-selectin ligation is necessary for 
this process.  
Leukocyte binding to E-selectin is known to induces signaling pathways which trigger the 
extravasation cascade in endothelial cells via “outside-in” signaling engaging MAPK, PLC-γ, 
Erk/Src or MLC/p38 pathways (27,38). These signaling events promoted increased 
monolayer permeability through a disruption of VE-cadherin/β-catenin complex or formation 
of stress fibers which both facilitated trans-endothelial migration (10,39). Here we observed 
that monocytes assist tumor cells to induce cytoskeletal retraction in endothelial cells in an E-
selectin dependent manner. In addition, depletion of monocytes before tumor cell injection 
prevented increase in lung permeability strongly suggesting that E-selectin and monocytes 
are important regulators of pulmonary vascular permeability in response to tumor cells. 
Recently, it was reported that factors released from a primary tumor up-regulate expression 
of E-selectin and focal adhesion kinase to form hyperpermeable foci where tumor cells can 
extravasate (14). We also detected reduced pulmonary metastasis in tumor bearing E-sel-/- 
mice which further confirms the role of E-selectin during metastasis. Taken together, E-
selectin-mediated interactions between endothelium and leukocytes in combination with 
induced CCL2 expression critically affect the shaping of a metastatic niche which facilitates 
tumor cell extravasation and initiates successful development of secondary tumors. 
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Figure legends 
Figure 1. Tumor cells with no E-selectin ligands metastasize in E-selectin dependent 
manner. Mice were intravenously injected with tumor cells and lungs analyzed for 
metastasis. A) Representative images of dissected lungs 28 days after MC-38GFP cell 
injection. B) Quantification of metastatic foci. Representative images of lungs of mice 
injected with 3LL (C) or B16-BL6 cells (E) after 14 days. Quantification of metastatic foci in 
3LL (D) and B16-BL6 injected mice (F). *; p<0.05; ***; p<0.001. 
Figure 2. E-selectin dependent leukocyte recruitment to the metastatic organ. A-C) 
Flow cytometry analysis of lung homogenates from C57BL/6 and E-sel-/- mice at 24 or 48 
hours p.i. were compared to lungs of naïve mice, respectively. The number of total infiltrated 
leukocytes (CD45+), inflammatory monocytes (Ly6Chigh) and macrophages (F4/80+) was 
normalized to 1’000 endothelial cells (CD31+). D-F, Lung analysis for macrophages (F4/80+) 
(D) and granulocytes (Ly6G+) (E) at 16 and 24 hours p.i. were compared to naïve lungs. F) 
Representative images of F4/80+ cells (red) in lungs of C57BL/6 and E-sel-/- mice at 16 or 24 
hours p.i. compared to naïve lungs of respective strain. Nuclei (blue) are stained with DAPI. 
Scale bar = 20 μm. G) Quantification of tumor cells in lung sections prepared from mice 16 or 
24 hours p.i. Data are presented as mean ± SEM. *; p<0.05. 
Figure 3. Tumor cell-induced E-selectin expression facilitates specific leukocyte 
association with tumor cells at metastatic sites. A) E-selectin expression in the whole 
lungs isolated from C57BL/6 mice at 6, 12 and 24 hours p.i. were compared to lungs of naïve 
mice. Expression levels determined by real-time PCR were normalized to GAPDH 
expression. Data are expressed as mean ± SEM. ***; p<0.001 by ANOVA. B) Confocal 
microscopy images of E-selectin expression (red) in the vicinity of tumor cells (green) on lung 
sections at indicated times p.i. Nuclei (blue) were stained with DAPI. Bar = 10 μm. C) 
Confocal microscopy of lung sections 6 h p.i. Tumor cells (green) were associated with 
CD11b+ cells (white) in the vicinity of E-selectin+ (red) endothelial cells. Nuclei (blue) were 
stained with DAPI. D) Analysis of tumor cell-leukocyte association in lungs of C57BL/6 and 
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E-sel-/- mice 16 and 24 hours p.i. Inset: Image of a tumor cell (green) in contact with F4/80+ 
cells (red) in lungs of mice 16 hours p.i. Nuclei (blue) are stained with DAPI. Bar = 10 μm. E) 
Microscopic image of MC-38GFP cells (green) attached to an endothelial monolayer in a 
microfluidic device (left panel). Representative images of tumor cells (green) adherent on 
endothelial cells derived from C57BL/6 (middle panel) and E-sel-/- mice (right panel) and 
recruited monocytes (red) 50 minutes after initiation of monocyte perfusion. F) Number of 
MC-38GFP cells associated with monocytes on endothelial cells at 15, 50 and 90 minutes 
after perfusion with monocytes was induced in a microfluidic device. G) Number of 
monocytes associating with a single tumor cell attached to endothelial cell monolayers at 
indicated times. H) Number of tumor cells quantified on lung sections from mice 16 or 24 
hours p.i. Data are presented as mean ± SEM.  *; p<0.05; ***; p<0.001. 
Figure 4. E-selectin expression is induced through tumor cell-derived CCL2 and 
further endothelial activation facilitates increase in CCL2 chemokine pool in 
metastatic lungs. A-D) Total RNA was isolated from the whole lungs of untreated C57BL/6 
and E-sel-/- mice and 6, 12 and 24 hours p.i. Expression levels of VCAM-1 (A), ICAM-1 (B), 
CCL2 (C) and CCR2 (D) were analyzed by real-time PCR and normalized to GAPDH. E-G) 
Total RNA was isolated from the whole lungs of untreated C57BL/6 mice and 6 hours p.i. 
with MC-38GFP and MC-38GFP CCL2 KD cells, respectively. Expression levels of E-selectin 
(E), VCAM-1 (F), CCL2 (G) were analyzed by real-time PCR and normalized to GAPDH. *; 
p<0.05; **; p<0.01. H-I) CCL2 protein levels in the perfused lung homogenate of untreated 
C57BL/6, E-sel-/- and Ccl2-/- mice 6 hours (H) and 12 hours p.i. (I) detected by cytokine bead 
array. CCL2 protein levels are normalized to total protein content. n = 3; *; p<0.05; **; 
p<0.01; ***; p<0.001 by ANOVA. J), CCL2 expression levels in pulmonary endothelial cells 
and inflammatory monocytes sorted from digested lungs of untreated C57BL/6 and E-sel-/- 
mice and 12 hours p.i. Data were analyzed by real-time PCR and normalized to GAPDH. 
Data are presented as mean ± SEM. n = 3; **; p<0.01 by Student’s t-test.  
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Figure 5. E-selectin expression promotes increased lung vascular permeability and 
facilitates tumor cell transmigration in monocyte-derived selectin ligand dependent 
manner A) Macroscopic images of lungs from untreated C57BL/6 and E-sel-/- mice and 24 
hours p.i. injected with Evans blue. C) Macroscopic images of lungs from untreated or 
clodronate liposome treated C57BL/6 mice 24 hours p.i. injected with Evans blue. B and D) 
Spectrophotometric quantification of Evans blue extracted from perfused lungs. E) Number of 
MC-38GFP cells transmigrated through lung endothelial cells derived from C57BL/6 and E-
sel-/- mice in the absence or presence of monocytes after 16 hours of co-culture. F) 
Representative images of transmigrated MC-38GFP cells (green) counted on the lower side 
of the transwell membrane. G) Number of MC-38GFP cells transmigrated through lung 
endothelial cells derived from C57BL/6 mice in the presence of monocytes. Normal (unfixed) 
monocytes were compared to fixed monocytes derived from C57BL/6 or Fuc-TVII-/- mice after 
16 hours of co-culture. Data are presented as mean ± SEM. **; p<0.01; ***; p<0.001; ns = not 
significant. 
Figure 6. E-selectin-dependent endothelial cell retraction is induced by tumor cells 
and monocytes. A-B) Representative images of Phalloidin-FITC stained cytoskeleton 
(green) of endothelial cells, derived from C57BL/6 (A) or E-sel-/- (B) mice, after co-culture 
with MC-38 cells (TC, red) and/or monocytes for 8 hours. Arrowheads indicate retracting 
endothelial cells. Bar = 50 μm. C) High power images of endothelial cells from C57BL/6 mice 
with MC-38 cells (red) and monocytes, showing endothelial cell retraction stained by 
Phalloidin-FITC (arrows) and the adjacent monocytes (arrowheads) after co-culture for 8 
hours. Nuclei (blue) are stained with DAPI. Bar = 20 μm. D) Quantification of endothelial cell 
retraction stained with Phalloidin-FITC of untreated endothelial cells from C57BL/6 or E-sel-/- 
mice (ctrl); or after co-culture with MC-38 cells (TCs) and/or monocytes (monos). Data are 
presented as mean ± SEM. ***; p<0.001 by ANOVA with the post-hoc Bonferroni multiple 
comparison test.  
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Figure 7. E-selectin facilitates spontaneous lung metastasis of Lewis lung carcinoma. 
A) Representative images of dissected lungs from C57BL/6 and E-sel-/- mice and H&E 
stained lung sections. B) Number of metastatic foci in lungs of tumor bearing C57BL/6 and 
E-sel-/- mice 30 days after subcutaneous injection of LLC1 cells. **; p<0.01. C) Scheme of E-
selectin-mediated interactions contributing to metastasis. 1) Tumor cells in circulation 
interact with platelets and leukocytes, eventually forming emboli that get trapped in the 
microvasculature. Shear stresses together with tumor-cell derived factors, e.g. CCL2, 
activate the endothelium resulting in E-selectin expression. 2) E-selectin on the endothelial 
cell surface mediates adhesion of leukocytes, which are recruited by tumor- and host-derived 
chemokines such as CCL2. Upon ligation of E-selectin by leukocytes “outside-in” signaling is 
induced both in leukocytes and in endothelial cells starting the extravasation cascade. 3) 
This includes firm adhesion of leukocytes to endothelium via integrin and VCAM-1/ICAM-1 
interaction as well as cytoskeletal remodeling and retraction in endothelial cells. Ultimately 
tumor cells extravasate through the permeable vasculature.  
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Figure S1. A) Murine tumor cells do not express E-selectin ligands. Representative histograms of 
E-, P-, and L-selectin binding to MC-38GFP, 3LL, B16-BL6 and LLC-1 cells using recombinant mouse 
selectins analyzed by flow cytometry. Filled areas represent control profiles with secondary antibodies 
only. Solid lines represent selectin-stained cells. Dashed lines represent selectin staining in the 
presence of 10 mM EDTA (negative control). B) Metastatic tumor burden in mice injected with MC-
38GFP cells. Quantification of metastatic load by measurement of GFP fluorescence in lung 
homogenates of C57BL/6 and E-sel
-/-
 mice 28 days after injection of MC-38GFP cells as previously 
described (1).   
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Figure S2 A) Gatig strategy for leukocyte populations in lungs after tumor cell injection. 
Leukocyte (CD45
+
) infiltration was quantified in relation to pulmonary endothelial cells (CD31
+
) used 
as an internal reference. B) Gating strategy for the quantification of leukocyte subpopulations 
infiltrated into lungs of C57BL/6 and E-sel
-/-
 mice after MC-38GFP injection. C) Representative flow 
cytometry plots of macrophages (left panel) and inflammatory monocytes (right panel) in lungs of mice 
at indicated time points after MC-38 GFP cell injection. D) Peripheral mononuclear blood cells of 
C57BL/6 and E-sel
-/-
 mice showed no difference. Representative flow plots of peripheral 
mononuclear blood cells in C57BL/6 and E-sel
-/-
 mice.   
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Figure S3. Microfluidic system work flow. Primary lung endothelial cells (ECs) were cultivated on a 
microfluidic slide, MC-38GFP cells were seeded on the confluent EC layer and 4 hours later the 
perfusion with monocytes in HEPES buffered Ringer solution supplemented with 25% washed red 
blood cells was started (2 dyne/cm
2
).  
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Figure S4. Tumor-cell derived CCL2 contributes to enhanced CCR2 expression in metastatic 
lungs. A) CCL2 expression levels in cultured MC-38GFP cells (WT) and MC-38GFP with silenced 
CCL2 (CCL2KD). Expression levels were analyzed by real-time PCR and normalized to GAPDH. B) 
CCR2 expression in whole lungs isolated from untreated C57BL/6 and 6 hours after WT-MC-38GFP or 
CCL2KD-MC-38GFP cell injection. C) CCL2 expression levels relative to GAPDH expression in sorted 
endothelial cells (ECs), and monocytes from untreated and tumor cell-injected mice 12 hours p.i. Data 
are presented as mean ± SEM. n= 3; *; p<0.05; **; p<0.01 by Student’s t-test. 
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Figure S5. Transmigration assay scheme. Tumor cells and bone marrow purified monocytes 
(CD115
+
 cells) in 3% FCS media are seeded to a confluent endothelial monolayer on a porous 
membrane of a transwell insert. Transmigrated tumor cells on the lower side of the membrane in the 
lower well containing 10% FCS media were counted. 
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Table S1. 
 
Primers  Sequences 5`-3` Fragment size (bp)  Tm (°C) 
E-sel CGCCAGAACAACAATTCCAC 157 60 
 ACTGGAGGCATTGTAGTACC  
 
CCL2 TTAACGCCCCACTCACCTGC 153 60  
 TGGGGTCAGCACAGACCTCTC 
 
CCR2  GCAAGTTCAGCTGCCTGCAAA 141 60  
  GTATGCCGTGGATGAACTGAGGT 
 
ICAM-1 CCCCGCAGGTCCAATTCACA 162 60 
 CCAAGCAGTCCGTCTCGTCC 
 
VCAM-1 GCGGTCTTGGGAGCCTCAAC 145 60  
 GTGACTCGCAGCCCGTAGTG 
 
GAPDH CCCAGCAAGGACACTGAGCAA 161 60 
 GTGGGTGCAGCGAACTTTATTGATG 
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Supplemental Experimental Procedures 
Selectin binding to tumor cells 
Selectin ligand staining on tumor cells was performed as described previously (2). Briefly, 
mouse selectin-Fc chimeras (L-, P-, and E-selectins) were pre-complexed with biotinylated 
goat anti-human antibody (1:100; Sigma-Aldrich) prior to incubation with tumor cells. Selectin 
binding was detected with Streptavidin-CyChrome (BD Biosciences). Control samples were 
incubated with selectin chimeras in the presence of 10 mM EDTA. Data were acquired on a 
BD FACSCanto II flow cytometer (BD Biosciences) and analyzed with the Flow Jo v8.8.4 
software (Tree Star).  
  
RESULTS  
107 
References 
 
1. Borsig, L., et al., Synergistic effects of L- and P-selectin in facilitating tumor metastasis can 
involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl 
Acad Sci U S A, 2002. 99(4): p. 2193-2198. 
2. Hoos, A., D. Protsyuk, and L. Borsig, Metastatic growth progression caused by PSGL-1-
mediated recruitment of monocytes to metastatic sites. Cancer Res, 2014. 74(3): p. 695-704. 
 
 
  
108 
 
  
DISCUSSION  
109 
DISCUSSION 
The interplay between tumor cells and their host environment is essential for all steps of the 
metastatic cascade, starting with the separation of tumor cells from the primary tumor mass 
and continuing with steps such as intravasation, survival in the circulation, adhesion to the 
microvasculature and ultimately tumor cell exit into the parenchyma (1). In this study we 
describe a novel mechanism whereby E-selectin exerts pro-metastatic effects via 
chemokine-assisted interactions with leukocytes at the metastatic site.  
 
1. E-selectin enables tumor cell arrest and adhesion in the microvasculature 
During the last decades several mechanisms concerning how selectins facilitate the 
metastatic process have been explored and demonstrate that selectins are important 
promoters of metastasis. E-selectin in particular has been strongly associated with 
metastasis and poor disease outcome in cancer patients which has been confirmed with 
experimental studies (2,3). E-selectins role as a promoter of metastasis has mostly been 
attributed to its binding to E-selectin ligands presented on tumor cells thereby enabling tumor 
cell arrest in the microvasculature, a prerequisite for efficient extravasation (4). Numerous 
experiments in vitro demonstrate that tumor cells bind to endothelial E-selectin under flow 
conditions (5-7) and the overexpression of selectin ligands on tumor cells resulted in 
increased metastasis in vivo (8,9). However, experimental data indicate that the initial arrest 
of tumor cells probably does not depend on active adhesion and may actually occur due to 
physical trapping of tumor cells in small capillaries (10). Lung metastasis assays have 
demonstrated that tumor cell arrest in the lung microvasculature seems to be an event 
occurring prior to endothelial activation and E-selectin up-regulation (11). This observation 
has raised the question to what extent E-selectin is actually involved during tumor cell arrest 
and whether E-selectin affects the metastatic cascade by other means. Our study sought to 
decipher the contribution of E-selectin to metastasis apart from its adhesive interactions with 
tumor cells by analyzing the effect of E-selectin on the early metastatic environment.  
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2. Early E-selectin-mediated processes promote metastasis 
We showed that experimental lung metastasis of tumor cells without E-selectin ligands was 
attenuated in E-selectin deficient mice. Using tumor cells without endogenous E-selectin 
ligands enabled us to exclude direct tumor cell-E-selectin adhesion as a promoter of 
metastasis in our experimental set up. Therefore, the observed reduction of metastatic 
nodules in absence of E-selectin indicates other activities of E-selectin during metastasis. An 
up-regulation of E-selectin has been reported in experimental lung metastasis models as an 
early event, occurring only a few hours after tumor cells are injected into the tail vein and 
diminishing within one day (11). In line with this data, we found that E-selectin mRNA and 
protein levels are up-regulated shortly after tumor cell injection which suggests that E-
selectin plays a role soon after tumor cell emboli arrest in the lungs. The number of observed 
tumor cells in the lung was already lower within less than a day in the absence of E-selectin. 
This led us conclude that E-selectin is involved during communication within the metastatic 
microenvironment and thereby supports tumor cells during early metastatic processes such 
as tumor cell extravasation. The up-regulation of E-selectin in the lungs was accompanied by 
increased VCAM-1 and ICAM-1 levels which are additional markers of endothelial activation 
elicited by tumor cell emboli. E-selectin deficient lungs showed decreased VCAM-1 and 
ICAM-1 levels upon tumor cell injection demonstrating minimal responsiveness of the 
endothelium to activation triggers.  
Markers of endothelial activation and inflammation are up-regulated only several hours after 
intravascular tumor cell arrest in experimental metastasis models (11-14). The inhibition of 
endothelial VCAM-1 and vascular adhesion protein-1 (VAP-1) has been recently reported to 
result in decreased myeloid cell recruitment and diminished tumor cell survival (14). Blocking 
endothelial activation had metastasis reducing effects (15,16). A possible explanation for the 
less activated endothelium observed in the absence of E-selectin might be a loss of signaling 
through pathways which are normally induced in stromal cells and contribute to an 
inflammatory environment.  
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Endothelial expression of E-selectin in response to tumor cells can be triggered by tumor cell 
emboli-produced shear forces or tumor cell-derived factors such as cytokines or chemokines 
(17). In this thesis we provide evidence that the tumor cell-derived chemokine CCL2 
contributes to E-selectin induction on the pulmonary vasculature by demonstrating that tumor 
cells with reduced CCL2 expression elicit weaker E-selectin up-regulation in lungs than wild 
type tumor cells. The exact mechanism behind CCL2-mediated E-selectin up-regulation is 
currently unknown. Chemokine production and E-selectin expression have been linked in 
several studies. One such study demonstrated that in a rat model of hyperhomocysteinemia, 
CCL2 and adhesion molecules including E-selectin were up-regulated and mediated the 
adhesion of monocytes to the aortic endothelium (18). p38 MAPKs have been reported to 
induced E-selectin expression (19) and inhibition of p38 MAPKs in stimulated endothelial 
cells led to reduced E-selectin and chemokine and cytokine expression including IL-8, CCL2 
and IL-6 (20). However, no detailed mechanistic pathway concerning the up-regulation of E-
selectin via CCL2 has been established. 
 
3. A link between E-selectin and the chemokine CCL2 during metastasis 
Numerous studies have reported that CCL2 regulates monocyte recruitment to metastasizing 
tumor cells (21-23) and that elevated CCL2 levels at metastatic sites are strongly associated 
with metastasis of several cancer types in vivo (21,24,25). Both tumor cell- and stromal cell-
derived CCL2 have been reported to recruit inflammatory monocytes to the lungs at early 
stages in various metastasis models (21,24). One possible explanation concerning CCL2s 
pro-metastatic activity is that it may interact with endothelial CCR2 thereby inducing 
increased vascular permeability that favors tumor cell extravasation (21).  
In our study CCL2 and CCR2 levels were both increased in C57BL/6 lungs early after tumor 
cell injection but only minimal changes were detected when E-selectin was absent. Tumor 
cell injection into mice without endogenous CCL2 expression only revealed a minor increase 
of CCL2 protein levels in lungs compared to C57BL/6 and E-selectin deficient mice. Given 
the comparable number of tumor cells in lungs of C57BL/6, E-selectin and CCL2 deficient 
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mice at this early time point the small CCL2 increase in CCL2 deficient mice corresponds to 
the tumor cell-derived CCL2. This suggests that besides tumor cells endogenous host cells 
contribute to CCL2 production in C57BL/6 and E-selectin deficient mice. Here, we identified 
stromal cells as the predominant source of CCL2 in response to tumor cell injection by 
showing that inflammatory monocytes as well as endothelial cells strongly provided the 
metastatic environment with CCL2. Its expression was also diminished in these cell types in 
the absence of E-selectin causing the reduced CCL2 pool in E-selectin deficient lungs after 
tumor cell injection. Host-derived CCL2 may be secreted as a result of endothelial activation 
and E-selectin is required for proper endothelial CCL2 up-regulation in response to tumor cell 
emboli. Whether E-selectin is directly linked to signaling pathways responsible for CCL2 
induction or E-selectin and the following activation state of the endothelium indirectly 
regulates endothelial CCL2 production needs to be further analyzed. One possible reason for 
decreased monocyte-derived CCL2 levels in E-selectin deficient mice may be a lack of 
monocyte activation. A study reported that monocyte-HUVEC interactions resulted in 
increased expression of CCL2 and IL-8, suggesting that once leukocytes adhered to the 
endothelium they may be activated by events of the extravasation cascade resulting in 
increased production of these chemokines (26). CCL2 is also well-known to trigger firm 
adhesion of monocytes to the vascular endothelium (27). Our results demonstrate an 
important role for E-selectin as an initiator of appropriate endothelial activation processes 
during metastasis. Thereby CCL2 production and E-selectin expression are linked and 
possibly participate in a positive feedback loop potentiating an inflammatory milieu. We 
believe that endothelial activation and E-selectin are essential for myeloid cell-derived CCL2 
secretion into the metastatic niche. For this reason we next investigated E-selectin-mediated 
interactions with leukocytes during metastasis.  
 
4. E-selectin-mediated leukocyte adhesion facilitates metastasis 
Leukocytes in the metastatic niche are considered to be important contributors during 
metastasis since many studies have shown that recruitment and activation of immune cells, 
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especially inflammatory monocytes, are strongly associated with enhanced metastatic 
colonization. Monocytes are either recruited by primary tumors to metastatic target sites or 
attracted by intravascular tumor cells. They are a critical source of various soluble factors 
such as growth factors, matrix degrading enzymes, cytokines and chemokines and have 
been reported to assist tumor cell survival in the microvasculature and transmigration 
through the endothelium (21,28-32). In our study, we showed that the recruitment of myeloid 
cells, including macrophages, inflammatory monocytes and granulocytes, to metastatic sites 
is E-selectin-dependent since less of these myeloid cell populations were found in the lungs 
of E-selectin deficient mice within the first 2 days after tumor cell injection. On one hand this 
could be a consequence of weaker endothelial cell activation and therefore reduced CCL2 
levels. On the other hand, a lack of E-selectin and diminished CCL2 levels could prevent 
efficient capturing and firm adhesion of recruited monocytes. We demonstrated reduced 
tumor cell-leukocyte association at metastatic sites in E-selectin deficient mice, indicating 
that the local recruitment of leukocytes to tumor cells is E-selectin-dependent. Accordingly, 
flow adhesion experiments in vitro demonstrated less monocytes associating with tumor cells 
on E-selectin deficient endothelial monolayer. Based on these results, vascular E-selectin 
directly regulates the adhesion of leukocytes in the vicinity of tumor cells whereby leukocytes 
probably get activated leading to CCL2 secretion. 
 
5. Interactions between E-selectin and ligands on monocytes induce vascular 
permeability and tumor cell transmigration 
Previous studies have already revealed that selectin-mediated leukocyte interactions strongly 
support metastasis during early stages. Decreased leukocyte-tumor cell interactions and 
impaired early tumor cell seeding have been observed in L-selectin deficient mice (33). In 
mice unable to induce L-selectin ligand expression at sites of intravascular tumor cell arrest 
metastasis is attenuated (29). Mice lacking fucosyltransferase-4/7 have no endogenous 
selectin ligands on leukocytes and exhibit less recruitment of monocytes to the metastatic 
microenvironment and attenuated metastasis (32). This study demonstrates that metastasis 
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is promoted by monocytes interacting with the endothelium. The role of monocytes during 
metastasis has been elaborated recently whereby tumor cell-derived CCL2 signals via 
endothelial CCR2 and thereby promotes tumor cell extravasation (21). The JAK2-Stat5-p38 
MAPK signaling pathway is activated in the CCR2 expressing endothelial cells via concerted 
actions of tumor-cell derived CCL2 and inflammatory monocytes, consequently increasing 
vascular permeability and driving tumor cell transmigration. Whether only tumor-cell secreted 
CCL2 or also monocyte or endothelial CCL2 contributes to the activation of the JAK2-Stat5-
p38MAPK pathway is not known. Also the role of interactions between E-selectin on 
endothelial cells and its ligands on monocytes was not analyzed in this study but it’s quite 
conceivable that they might participate in triggering these signaling events.  
In our study we observed enhanced monocyte-assisted tumor cell transmigration in vitro in 
the presence of E-selectin on the endothelium which was diminished when E-selectin was 
missing on the endothelium. Non-viable (fixed) monocytes which display ligands, including 
those for E-selectin, on their surface as well as fucosyltransferase-7 deficient monocytes with 
a limited amount of selectin ligands were able to support tumor cell transmigration. Fixed 
fucosyltransferase-7 deficient monocytes didn’t assist tumor cells to transmigrate. These 
observations show that E-selectin ligands on monocytes and soluble factors from viable 
monocytes are required for efficient tumor cell transmigration. It is well known that the 
interaction of ligands on leukocytes with endothelial E-selectin induces signaling pathways 
which initiate the extravasation cascade in endothelial cells via “outside-in” signaling. This 
has been demonstrated by many studies in vitro using HUVECs whereby E-selectin-ligand 
interactions lead to signaling in endothelial cells via MAPK, PLC-γ, Erk/Src and MLC/p38 
(34,35). These signaling events promote increased monolayer permeability (36) due to 
disruption of VE-cadherin/β-catenin complexes or the formation of stress fibers which both 
facilitate trans-endothelial migration (37,38). Consistent with these findings, we demonstrate 
that monocytes assist tumor cells by inducing cytoskeletal retraction in endothelial cells by 
interacting with E-selectin. This effect was diminished in the same experimental set up using 
E-selectin deficient endothelial cells. Our results indicated that E-selectin on endothelial cells 
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constitutes an important initiator of the extravasation cascade via its interaction with ligands 
on monocytes, resulting in signal transduction in endothelial cells as well as in monocytes 
which manipulates both cell types in a way that promotes tumor cell extravasation.  
We discovered that induction of vascular permeability requires E-selectin in vivo since we 
observed almost no permeability changes in the lungs of E-selectin deficient mice upon 
tumor cell injection. We obtained similar results when we depleted monocytes prior to tumor 
cell injection indicating that endothelial E-selectin and monocytes are necessary for induction 
of pulmonary vascular permeability in response to tumor cells. These findings support the 
notion that E-selectin-mediated leukocyte adhesion and the resulting signaling cascade in 
the endothelium and leukocytes crucially modulate vascular integrity during metastasis. 
 
6. E-selectin involvement during later stages of metastasis 
Our results demonstrate that E-selectin also regulates the incidence of spontaneous 
metastasis. We demonstrated this in tumor bearing E-selectin deficient mice that had 
decreased lung metastasis. We therefore conclude that E-selectin plays a further role during 
“natural” spreading of primary tumors. It was reported that primary tumor factors can up-
regulate E-selectin and the focal adhesion kinase to form hyperpermeable foci where tumor 
cells can extravasate (39). Further evidence is required to determine whether E-selectin 
regulates spontaneous metastasis through the same mechanisms we investigated with our 
experimental metastasis model or whether E-selectin has additional effects during 
metastasis development.  
There is evidence that E-selectin is involved during essential events of angiogenesis as 
several studies have linked E-selectin with endothelial proliferation, (40,41) migration (42), 
and tube formation (43). Down-regulation of E-selectin resulted in diminished endothelial 
progenitor cell homing, tumor angiogenesis and tumor growth in transplantation models of 
human melanoma xenografts into mice (44). However the role of E-selectin during 
spontaneous metastasis, especially regarding growth of secondary tumors requires further 
evaluation. In addition, it would be of great interest to elucidate the interplay between cells of 
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the adaptive immune system and E-selectin expressing endothelial cells during early and late 
stages of metastasis. Some preliminary results of ours show attenuated experimental lung 
metastasis in Rag1 deficient mice (lacking mature lymphocytes) compared to C57BL/6 mice. 
This effect is even greater in Rag1/E-selectin double deficient mice.  
 
7. Conclusion and outlook 
This thesis describes a novel mechanism whereby vascular E-selectin assists tumor cells 
during extravasation by interacting with leukocytes at the metastatic site. Based on our 
results we propose the course of events illustrated in Figure 1: Tumor cells undergo 
intravascular arrest and produce CCL2 which activates endothelial cells which in turn up-
regulate endothelial E-selectin expression. On one hand this triggers further CCL2 
production by endothelial cells and on the other hand inflammatory monocytes are recruited 
to the metastatic sites in response to tumor- and endothelial cell-derived CCL2 and other 
factors. Recruited monocytes bind to E-selectin via surface ligands which enables their 
adhesion to the microvasculature and triggers signaling events both in endothelial cells and 
monocytes. In activated monocytes CCL2 production is further amplified while E-selectin-
ligand interactions activate signaling pathways that lead to cytoskeletal rearrangement and 
consequently retraction of endothelial cells. Besides, CCL2 in the metastatic niche also 
enhances the firm adhesion of monocytes (mediated by integrin-VCAM-1/ICAM-1 
interactions) and contributes to breaching of the vascular barrier. Finally, tumor cells 
extravasate through local vascular openings and colonize the lung parenchyma (Figure 1). 
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Figure 1. E-selectin mediated interactions with leukocytes facilitate tumor cell transmigration.  
 
Thus, E-selectin-mediated interactions between the endothelium and leukocytes in 
combination with CCL2-mediated signaling during the metastatic process play a critical role 
as “architects” of the metastatic niche by enabling tumor cell extravasation and initiating the 
successful development of secondary tumors. Understanding mechanisms driven by E-
selectin-leukocyte interactions leading to metastasis will help to improve our understanding 
of the complex processes taking place during tumor spreading and offer new prospects for 
future clinical applications. 
 
Our findings gave rise to several additional questions: 
o What are the signaling pathways that are responsible for the tumor cell-derived 
CCL2-mediated up-regulation of E-selectin in the vasculature?  
o How does E-selectin in turn trigger CCL2 expression by endothelial cells? 
o How does the endothelial E-selectin-leukocyte ligand interaction induce CCL2 
expression by leukocytes? 
o Can E-selectin-leukocyte ligand interactions be pharmacologically impeded to prevent 
metastasis formation? 
Hence, continuing investigations will provide more mechanistic details and might help to 
therapeutically target specific interactions involving endothelial E-selectin during metastasis.  
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